

## AUTHOR INDEX

**Page references to clinical nephrology meetings abstracts in journal number 4 are preceded by 4:A.**

**Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.**

Aamodt, K., 4:A2, 4:A9  
Abdalla, A. H., 631  
Abe, K., 843  
Ábrahám, Gy., 4:A3, 4:A5  
Abu-Aisha, H., 866  
Ackrill, P., 593  
Adams, N. D., 4:A3, 4:A5  
Agodoa, L. Y., 720  
Agraharkar, M., 4:A3, 4:A5  
Aguilera, A., 569  
Akhtar, M., 115  
Akmal, M., 223  
Albalate, M., 392  
Alcázar, R., 239  
Alexiewicz, J. M., 233  
Al-Hawas, F., 631  
Al-Khader, A. A., 631  
Alkhunaizi, A. M., 936  
Allen, A. C., 285  
Al-Momen, A., 866  
Alpern, R. J., 291  
Al-Sulaiman, M. H., 631  
Al-Tuwajiri, A., 866  
Al-Wakeel, J., 866  
Amini, M., 277  
Ancarani, E., 277  
Anderson, L., 739  
Andreoli, S. P., 817  
Aparicio, M., 285  
Appel, L. J., 720  
Apple, F. S., 399  
Aronoff, G. R., 907  
Arrigo, G., 27  
Askepidis, N., 4:A2, 4:A19  
Assmann, K. J. M., 4:A3, 4:A16  
Atkinson, R., 560  
Audrain, M. A. P., 125  
Avecillas, J. F., 4:A4, 4:A11  
Averbukh, J., 230  
Avram, M. M., 4:A1, 4:A5  
Ayoub, E. M., 355  
Ayus, J. C., 4:A4, 4:A14  
  
Baddoura, F. K., 4:A3, 4:A16  
Badran, N., 4:A2, 4:A16  
Bailey, T. C., 428  
Bakris, G. L., 803  
Balfe, J. W., 136  
Baliga, R., 465  
Baluarte, H. J., 4:A1, 4:A6  
  
Bansal, V. K., 193  
Baragetti, I., 490  
Baranger, T., 125  
Bárány, P., 565  
Bargman, J. M., 620  
Barkeling, B., 691  
Barnes, R., 739  
Baronti, R., 4:A1, 4:A6  
Barré, P., 214  
Barrett, B. J., 214  
Barri, Y. M., 773  
Barrientos, A., 541  
Bartlett, S. T., 739  
Bastacky, S. I., 334  
Bastani, B., 947  
Battie, D., 4:A2, 4:A20  
Bays, H., 907  
Bazzi, C., 27  
Beaver, S. K., 851  
Becker, B., 4:A1, 4:A7  
Becker, G., 912  
Bellovich, K., 461  
Beltrame, A., 27  
Bender, F. H., 685  
Bereczki, C., 4:A3, 4:A5  
Bergström, J., 565  
Berlyne, G. M., 4:A1, 4:A10  
Bertani, T., 254  
Besarab, A., 223  
Best, J., 54  
Beto, J. A., 193  
Bianchi, G., 490  
Blanco, M., 4:A1, 4:A5  
Blau, N., 36  
Boehmer, J. P., 280  
Boeschoten, E. W., 584  
Bojti, T., 4:A2, 4:A15  
Bolin, P., Jr., 624  
Bonventre, J. V., 66, 793  
Bordenave, K., 4:A2, 4:A20  
Borochovitz, D., 334  
Bouhaddi, M., 746  
Bradley-Guidry, C., 897  
Breborowicz, A., 404  
Brenes, L., 136  
Brennan, D. C., 428  
Bresson, C., 746  
Breyer, J. A., 167, 678  
Breznyak, W., 549  
Briceno, L. F., 136  
  
Brier, M. E., 907  
Briggs, W. A., 4:A3, 4:A12, 4:A17  
Brody, R. I., 514  
Brown, E. A., 4:A2, 4:A13  
Brown, W. W., 368  
Budde, K., 871  
Buller, G. K., 959  
Bumgardner, G. L., 419  
Burdick, J. F., 4:A3, 4:A17  
Burgess, E., 4:A3, 4:A9  
Burke, S. K., 66, 4:A1, 4:A6  
Burshell, A., 4:A2, 4:A11  
Butani, L., 4:A1, 4:A6  
  
Campbell, E., 942  
Canessa, M., 45  
Caprioli, R., 4:A1, 4:A6  
Caramelo, C., 392  
Carney, D., 4:A2, 4:A16  
Carreño, V., 392  
Carter, D., 4:A2, 4:A14  
Casado, S., 392  
Cattran, D. C., 200  
Ceska, M., 871  
Chalopin, J. M., 746  
Chan, R., 4:A1, 4:A4, 4:A10, 4:A11  
Chang, J. G., 769  
Chang, M.-H., 188  
Chapman, A., 936  
Charytan, C., 4:A2, 4:A18  
Chawla, H., 514  
Chayen, D., 230  
Chen, C.-H., 188  
Chen, W., 4:A3, 4:A7  
Chen, Y. S., 4:A3, 4:A7  
Chertow, G. M., 66  
Choi, M., 4:A3, 4:A12  
Chugh, S., 4:A3, 4:A7  
Cioni, L., 4:A1, 4:A6  
Cisterne, J.-M., 96  
Clive, D. M., 627  
Cohn, M., 230  
Collins, J. F., 456  
Colosio, V., 254  
Combe, C., 285  
Conneen, S., 4:A2, 4:A20  
Coomer, R. W., 4:A1, 4:A7, 678  
Copley, J., 4:A2, 4:A11  
Corna, D., 254  
Coroneos, E., 132

Cosio, F. G., 419  
 Covic, A. C., 593  
 Cowley, B. D., Jr., 265, 435  
 Coxon, V., 207  
 Crook, E. D., 4:A3, 4:A19  
 Cruz, D. N., 759  
 Curtis, J. J., 608  
 Cutler, R. E., 897  
 Daboczi, A., 4:A4, 4:A10  
 D'Agati, V., 119  
 Dahlmeier, B. A., 399  
 Dai, Z., 4:A3, 4:A16  
 D'Amico, G., 27  
 Danatal, J., 125  
 Danpure, C. J., 36  
 Darragh, T. M., 754  
 Dash, T., 445  
 Davies, E. A., 419  
 Dekker, F. W., 584  
 De la Torre, M., 239  
 Dell'Antonio, G., 490  
 Deminière, C., 285  
 Demko, T. M., 280  
 Depner, T. A., 658  
 De Sequera, P., 392  
 Detwiler, R. K., 624  
 Dheenam, S., 4:A1  
 Diamond, J. R., 280  
 DiBenedetto, A., 881  
 Di Francesco, G., 4:A1, 4:A8  
 Di Iorio, B., 4:A1, 4:A8  
 Dillon, M. A., 4:A1, 4:A6  
 Distant, D. A., 881  
 Donadelli, R., 254  
 Donadio, J., 817  
 Dotson, L., 106  
 Doyle, G. D., 942  
 Dressler, R., 119  
 DuBose, T. D., Jr., 793  
 Dumler, F., 685  
 Dumoulin, G., 746  
 Dunagan, W. C., 428  
 Dunn, S. R., 72  
 Durand, D., 96  
 Eiam-Ong, S., 4:A4, 4:A8  
 Eknayan, G., 6:xxxxix  
 Elkhammas, E. A., 419  
 Ellison, D. H., 959  
 Emancipator, S. N., 817  
 Eqbal, A., 334  
 Esnault, V. L. M., 125  
 Evans, D., 739  
 Faber, S., 533  
 Faccinetti, D., 254  
 Falkenhain, M. E., 419  
 Falkner, B., 45  
 Faraggiana, T., 277  
 Farrell, J., 947  
 Favilla, G., 4:A1, 4:A6  
 Feehally, J., 285  
 Fehmi, H., 4:A2, 4:A20  
 Feldman, C., 4:A2, 4:A12  
 Ferguson, R. M., 419  
 Feriozzi, S., 277  
 Fernik, E., 78  
 Fervenza, F., 273  
 Figueroa, J., 4:A2, 4:A11  
 Filangeri, J., 4:A2, 4:A18  
 Filho, J. C. D., 565  
 Fine, A., 103, 214  
 Fine, B., 4:A1, 4:A9  
 Finelli, A., 620  
 Finger, M., 4:A1, 4:A11  
 First, M. R., 303  
 Fischer, F.-P., 246  
 Fish, A., 4:A4, 4:A20  
 Fishbane, S., 319  
 Flanigan, M. J., 383  
 Foda, H., 449  
 Fogo, A., 806, 966  
 Földes, K., 4:A4, 4:A14  
 Fong, I., 763  
 Forero, N., 4:A2, 4:A16  
 Fotiadis, C., 4:A1, 4:A7  
 Fournier, V., 746  
 Frankenfield, D., 851  
 Fraser, I., 912  
 Frederick, P. R., 851  
 Freedman, B. I., 729  
 Friedman, E. A., 549, 881  
 Fryer, P., 36  
 Fujii, T., 733  
 Gabuzda, G. M., 72  
 Gallo, G., 514  
 Garlick, P., 712  
 Gassman, J. J., 888  
 Gattone, V. H., II, 265, 435  
 Ger, Y.-C., 345  
 Gertner, R., 514  
 Glasscock, R. J., 633, 720, 817  
 Goldberg, D. I., 66, 4:A1, 4:A6  
 Goldfarb, D. S., 514  
 Goldsmith, D. J. A., 593  
 Goldstein, M. B., 214  
 Goligosky, M. S., 712  
 Gottlieb, R. H., 362  
 Gruber, M., 449  
 Grande, J. P., 817  
 Grantham, J. J., 435  
 Graves, G. S., 773  
 Greco, B. A., 167  
 Green, A., 273  
 Greenberg, A., 334  
 Grim, C., 720  
 Groff, J. A., 280  
 Grossman, E. B., 362  
 Grubb, B., 4:A1, 4:A8  
 Guella, A., 115  
 Haegerstrand, A., 78  
 Halevy, A., 230  
 Hall, W. D., 720  
 Halperin, M. L., 136  
 Halpern, Z., 230  
 Hammerman, M. R., 793  
 Handa, S. P., 214  
 Hara, N., 345  
 Hare, I., 533  
 Hargrove, G., 4:A3, 4:A9  
 Hart, J., 739  
 Hartman, K., 739  
 Hass, M., 829  
 Hedrick, C., 355  
 Helgerson, S. D., 851  
 Henrich, W. L., 4:A1, 4:A8  
 Henry, M. L., 419  
 Hernandez, B., 4:A2, 4:A14  
 Herrero, J. A., 541  
 Hewitson, T., 912  
 Hickman, M., 4:A1, 4:A9  
 Hilgers, K. F., 376  
 Hill, S., 503  
 Hirose, H., 86  
 Ho, K. K. L., 699  
 Hodgson, C., 4:A2, 4:A18  
 Hoeft, P., 399  
 Hoehn-Saric, E., 739  
 Hoffmann, E. O., 4:A4, 4:A16  
 Holley, J. L., 685  
 Hong, J. H., 881  
 Hoppe, B., 36  
 Horberger, J., 4:A2, 4:A12  
 Horn, R. G., 806  
 Hory, B., 746  
 Hsu, C. H., 641  
 Huang, T.-P., 769  
 Huraib, S., 866  
 Hussain, S. T., 4:A4, 4:A20  
 Husserl, F., 4:A2, 4:A11  
 Hutchinson, F. N., 651  
 Hylander, B., 691  
 Ifudu, O., 549  
 Igarashi, M., 526  
 Ilamathi, E., 4:A1, 4:A11  
 Inenaga, T., 733  
 Ing, T. S., 288  
 Inoue, T., 733  
 Isoda, K., 86  
 Itoyama, S., 86  
 Jacobson, E. J., 4:A2, 4:A9  
 Jacobson, S. H., 78  
 Jaekels, J., 739  
 Jager, K. J., 584  
 Járay, J., 4:A4, 4:A10, 4:A14,  
 4:A15  
 Javit, D. J., 4:A4, 4:A11  
 Jenei, Z., 4:A2, 4:A15

Jenkins, P. G., 4:A1, 4:A10  
 Jennings, P. R., 36  
 Jenson, B. M., 576  
 Jindal, K. K., 214  
 Johnson, J. P., 334  
 Johnson, L. B., 739  
 Johnson, M., 763  
 Johnson, R. J., 147  
 Jones, B., 553  
 Jones, K., 897  
 Jones, W. J., 651  
 Jordan, W., 947  
 Joseph, A., 4:A1, 4:A10  
 Julian, B. A., 608

Kais, H., 230  
 Kaiser, B., 4:A1, 4:A6  
 Kakuk, Gy., 4:A2, 4:A15  
 Kamel, K. S., 136  
 Kammer, G. M., 729  
 Kamran, A., 4:A1, 4:A10  
 Kaneta, S., 435  
 Kao, K. J., 355  
 Kaplan, R. M., 888  
 Kapoian, T., 479  
 Karón, J., 404  
 Karp, H., 368  
 Kasuno, K., 931  
 Katalinic, A., 871  
 Katayama, H., 4:A4, 4:A20  
 Kathuria, P., 106  
 Katona, É., 4:A2, 4:A15  
 Katsinas, C., 4:A2, 4:A19  
 Kawamura, S., 345  
 Kaysen, G. A., 658  
 Keilarri, T., 4:A2, 4:A20  
 Keystone, J., 620  
 Khairullah, Q. T., 383  
 Kharasch, E., 4:A1, 4:A12  
 Kim, Y., 4:A4, 4:A20  
 Kimura, G., 733  
 Kindos, P., 4:A1, 4:A10  
 Kirk, K. A., 720  
 Kirsch, M., 4:A1, 4:A11  
 Kjellstrand, C. M., 214, 669  
 Klassen, D. K., 739  
 Kletke, P. R., 781  
 Knight, D. F., 368  
 Knochel, J. P., 773  
 Knoll, G. A., 608  
 Kobayashi, M., 526  
 Kohan, D. E., 2  
 Kolecki, R. S., 72  
 Kollár, L., 4:A3, 4:A14  
 Kon, V., 817  
 Konieczny, T., 4:A3, 4:A16  
 Kooh, S. W., 136  
 Kovács, T., 4:A3, 4:A14  
 Kovithavongs, C., 669  
 Koyama, A., 526  
 Kozak, M., 280

Krediet, R. T., 584  
 Krieger, J. N., 207  
 Kronmal, R. A., 207  
 Kuhlmann, U., 246  
 Kumar, A., 514  
 Kuo, P. C., 739  
 Kurtzman, N. A., 1  
 Kürzdörfer, M., 871  
 Kusek, J. W., 720  
 Kushner, H., 45  
 Kuwahara, T., 931

Lafayette, R. A., 273, 445  
 Lai, K. B., 699  
 Lai, K. N., 91, 699  
 Lakkis, F. G., 4:A3, 4:A16  
 Lam, C. W. K., 699  
 Langenfeld, M. R. W., 376  
 Lasseur, C., 285  
 Lasuncion, M. A., 569  
 Latif, S., 461  
 Laurel, M., 763  
 Lavie, R. H., 4:A4, 4:A11  
 Lázár, N., 4:A4, 4:A14  
 Lazarus, J. M., 66  
 LeBeau, S. O., 410  
 Lee, J. Y., 608  
 Lee, P., 54  
 Lee, P.-I., 188  
 Lee, S. M. K., 953  
 Leehey, D. J., 288  
 Le Mao, G., 96  
 Lennert, T., 777  
 Leumann, E., 36  
 Leung, C. B., 91  
 Leung, J. C. K., 699  
 Levin, A., 214, 533  
 Levison, S., 45  
 Levy, E., 453  
 Lewis, M., 533  
 Li, P. K. T., 91  
 Lim, V. S., 383  
 Lin, G., 230  
 Lindberg, J., 4:A2, 4:A11, 4:A18  
 Lippi, A., 4:A1, 4:A6  
 Llach, F., 496  
 Lochhead, K., 4:A1, 4:A12  
 López, D. G., 392  
 Lopez, T., 4:A1, 4:A8  
 Lu, M.-Y., 188  
 Luft, F. C., 777  
 Lundahl, J., 78  
 Lundin, A. P., 4:A1, 4:A10  
 Luzzana, E., 254

McCann, L., 4:A2, 4:A12  
 McCarthy, J. T., 576  
 McClellan, W. M., 368, 851  
 McClendon, E., 549  
 McCrary, R., 4:A1, 4:A9  
 McDonald, B. R., 615  
 Macey, L. J., 549

McLaughlin, K., 553  
 McMullan, M., 851  
 McNurlan, M., 712  
 Mactier, R., 553  
 Maesaka, J. K., 319  
 Maffi, R., 254  
 Majkowski, N. L., 706  
 Mandin, H., 214  
 Manske, C. L., 601  
 Marcen, R., 569  
 Markell, M. S., 881  
 Marquez-Julio, A., 4:A2, 4:A11  
 Marriott, E., 392  
 Marshall, S., 119  
 Martin, P., 541  
 Martin, S. J., 125  
 Martinez, I., 496  
 Martinez, J. R., 435  
 Martis, L., 404  
 Masaki, K., 345  
 Massengill, S. F., 355  
 Massry, S. G., 223, 720  
 Mathew, S., 4:A3, 4:A12  
 Mathur, V. S., 754  
 Matsumura, O., 86  
 Matthew, J. J., 549  
 Mauer, M., 4:A4, 4:A20  
 Maursky, V., 881  
 Mayers, J. D., 549  
 Mazumdar, C., 4:A1, 4:A10  
 Mehrotra, R., 106  
 Mehta, R. L., 793  
 Memon, N., 866  
 Mendelssohn, D. C., 533  
 Mendley, S. R., 706  
 Merkus, M. P., 584  
 Mettang, T., 246  
 Michelis, M. F., 4:A1, 4:A4, 4:A10, 4:A11  
 Miles, A.-M. V., 881  
 Mirsa, M., 4:A2, 4:A13  
 Mitarai, T., 86  
 Mitch, W. E., 5:xlvi  
 Mitchell, H. C., 897  
 Mittman, N., 4:A1, 4:A5  
 Modesto, A., 96  
 Mohácsi, Cs. G., 4:A3, 4:A5  
 Molitoris, B. A., 793  
 Molnar, M., 4:A3, 4:A13  
 Monk, R. D., 362  
 Montenegro, J., 496  
 Moore, B., 4:A1, 4:A11  
 Mora, S., 490  
 Moreau, A., 125  
 Morgan, J., 214  
 Moritz, M., 4:A4, 4:A14  
 Morris, M., 456  
 Morrissey, E. C., 615  
 Mortiboy, P., 533  
 Mousa, D. H., 631  
 Muda, A. O., 277

Muessel, M. J., 265  
 Muirhead, N., 214  
 Murakawa, M., 86  
 Murarta, G. H., 4:A2, 4:A20  
 Murphy, B., 54  
 Myers, J., 4:A2, 4:A16  
 Myrthil, G., 966  
 Nagai, R., 200  
 Nagai, Y., 345  
 Nagao, S., 435  
 Nagy, J., 4:A3, 4:A13, 4:A14  
 Nakamura, K., 345  
 Nakamura, S., 733  
 Nakanishi, K., 345  
 Naquin, J., 4:A2, 4:A11  
 Narula, S., 4:A3, 4:A16  
 Nacosad Study Group, 584  
 Negri, M., 230  
 Nemes, B., 4:A4, 4:A14  
 Neu, L. T., 947  
 Neuhaus, T., 36  
 Neumayer, H.-H., 871  
 Nguyen, N. U., 746  
 Nicholls, K., 912  
 Nishida, Y., 919  
 Nolph, K. D., 106  
 Nuchikat, P., 4:A3, 4:A18  
 Obialo, C. I., 4:A2, 4:A14  
 Oda, H., 919  
 Oksman, F., 96  
 Oliver, B., 4:A3, 4:A19  
 Olivero, J., 132  
 Olorenshaw, I. M., 729  
 Olson, J. L., 754  
 O'Neal, D., 54  
 Ootaka, T., 843  
 Oreopoulos, 404  
 Ortega, H., 569  
 Ortiz, A., 392  
 Ortúñio, J., 569  
 Otti, T., 947  
 Páll, D., 4:A2, 4:A15  
 Paller, M. S., 793  
 Palmarini, D., 4:A1, 4:A6  
 Parfrey, P. S., 214  
 Parker, M. G., 445  
 Passlick-Deetjen, J., 246  
 Patterson, J., 103  
 Peces, R., 239  
 Pedagogos, E., 912  
 Perazella, M. A., 759, 959  
 Peresleni, T., 712  
 Perner, F., 4:A4, 4:A10, 4:A14, 4:A15  
 Pesavento, T. E., 419  
 Petrini, C., 27  
 Podder, H., 4:A4, 4:A10, 4:A14, 4:A15  
 Polgár, P., 4:A2, 4:A15  
 Polinsky, M., 4:A1, 4:A6  
 Polner, K., 4:A2, 4:A21  
 Poon, P., 699  
 Popov, D., 449  
 Porter, E., 533  
 Porter, J. R., 4:A4, 4:A16  
 Porteus, C., 553  
 Portolés, J., 541  
 Preese, L. M., 399  
 Provenzano, R., 461  
 Querques, M., 4:A1, 4:A8  
 Rabetoy, G. M., 615  
 Randall, O. S., 720  
 Rao, T. K. S., 549  
 Rasul, I., 620  
 Reaveley, D. A., 4:A2, 4:A13  
 Regnard, J., 746  
 Remuzzi, G., 254  
 Reydel, C., 549  
 Richards, R. J., 4:A4, 4:A16  
 Richardson, R. M. A., 214  
 Rindi, P., 4:A1, 4:A6  
 Rivera, M., 569  
 Rizza, V., 27  
 Rocco, M. V., 888  
 Rodela, H., 404  
 Rodrigo, J., 541  
 Ronco, P., 115  
 Ross, J., 4:A2, 4:A11  
 Rössner, S., 691  
 Rostaing, L., 96  
 Royal, H. D., 560  
 Rubens, D. J., 362  
 Rumsby, G., 36  
 Rupp, J. C., 265  
 Rutecki, G., 4:A3, 4:A18  
 Saad, T. F., 4:A2, 4:A16  
 Sabatini, S., 4:A4, 4:A8  
 Saffarian, N., 461  
 Sághy, L., 4:A3, 4:A5  
 Saint-Hillier, Y., 746  
 Saito, T., 843  
 Sakhaei, K., 291  
 Saleem, S., 4:A3, 4:A16  
 Salem, M. M., 4:A2, 4:A17, 862  
 Samaniego, M., 4:A3, 4:A17  
 Sanchez, M. I., 136  
 Sang, G. L. S., 669  
 Sansom, S. C., 971  
 Santoro, S. A., 560  
 Saracho, R., 496  
 Sárszegi, Z., 4:A3, 4:A14  
 Sato, H., 843  
 Saxena, R., 4:A3, 4:A18  
 Schaebler, R. W., 72  
 Scheel, P. J., Jr., 4:A3, 4:A12  
 Schenk, U., 246  
 Scherbenke, J., 793  
 Schiff, M., 685  
 Schlueter, W., 4:A2, 4:A20  
 Schmidt, R. J., 685  
 Schmieder, R. E., 376  
 Schnitzler, M. A., 428  
 Schoch, L., 947  
 Schubiger, G., 36  
 Schulman, G., 678, 720  
 Schweitzer, E. J., 739  
 Schwenk, M., 4:A2, 4:A18  
 Seed, M., 4:A2, 4:A13  
 Sehgal, A. R., 410  
 Sekine, S., 86  
 Senzaki, H., 931  
 Shah, S. V., 465  
 Shappell, S. B., 966  
 Sharkey, S. W., 399  
 Sherman, R., 223  
 Sherman, R. A., 479  
 Sherrard, D. J., 207  
 Shoemaker, J. D., 947  
 Shyr, U., 678  
 Shyr, Y., 4:A1, 4:A7  
 Sica, D., 897  
 Siegel, N. J., 793  
 Simenhoff, M. L., 72  
 Skeate, R., 399  
 Slatopolsky, E. A., 66, 4:A1, 4:A6  
 Sleasman, J. W., 355  
 Sloan, R., 907  
 Slowik, M., 4:A2, 4:A18  
 Smith, J., 4:A1, 4:A9  
 Smith, L., 456  
 Smith, R. D., 897  
 Smith, S., 4:A2, 4:A11  
 Smogorzewski, M., 233  
 Soldati, L., 490  
 Soma, J., 843  
 Sommer, B. G., 881  
 Sonkodi, S., 4:A3, 4:A5  
 Sótónyi, P., 4:A4, 4:A10, 4:A15  
 Spaić, S., 4:A2, 4:A19  
 Spinowitz, B. S., 4:A2, 4:A18  
 Spitznagel, E. L., 428  
 Spray, B. J., 729  
 Squillace, D. P., 576  
 Sreedhara, R., 4:A1, 4:A5  
 Stalker, D. J., 907  
 Stenzel, K. H., 66  
 Stevens, P., 584  
 Stevenson, F. T., 658  
 Stockard, J. D., 971  
 Stokes, M. B., 514  
 Striker, G. E., 793  
 Sugawara, A., 931  
 Suh, H., 712  
 Sumrani, N., 881  
 Superdock, K. R., 72  
 Surgue, T., 549  
 Svec, F., 4:A4, 4:A16  
 Szeto, C. C., 91, 699  
 Takahasi, H., 435

Tamura, H., 86  
 Tan, D., 392  
 Tanaka, A., 931  
 Tanaka, M., 345  
 Tankersley, M. R., 608  
 Tarn, D.-C., 769  
 Tastet, M., 4:A2, 4:A18  
 Tato, A., 569  
 Taylor, R., 4:A2, 4:A3, 4:A17, 4:A19  
 Tecuanhuey, L., 4:A2, 4:A16  
 Teele, R. L., 456  
 Teng, R.-J., 188  
 Terracciano, V., 4:A1, 4:A8  
 Teruel, J. L., 569  
 Testa, A., 125  
 Testa, D., 254  
 Theodoridis, M., 4:A2, 4:A19  
 Thomas, S., 246  
 Thomas, W., 601  
 Thompson-Bell, S., 897  
 Thompson, L., 207  
 Thylén, P., 78  
 Tokushima, H., 86  
 Torday, Cs., 4:A3, 4:A5  
 Török, K., 4:A3, 4:A14  
 Torralbo, A., 541  
 Tóth, K., 4:A3, 4:A14  
 Toto, R. D., 897  
 Touboura, M., 4:A2, 4:A19  
 Truong, L., 132  
 Tsau, Y.-K., 188  
 Tsouchnikas, I., 4:A2, 4:A19  
 Tsuzuki, D., 931  
 Túri, S., 4:A3, 4:A5  
 Tuttle, A. B., 729  
 Tzamaloukas, A. H., 4:A2, 4:A20  
 Ueda, N., 465  
 Ueda, S., 931  
 Ulan, R., 669  
 Urta, J. M., 239  
 Uzu, T., 733  
 Valderrábano, F., 6:xxxii  
 Vats, A., 4:A4, 4:A20  
 Vayonas, G., 4:A2, 4:A19  
 Vázquez, A., 392  
 Vella, J. P., 942  
 Venkatesan, J., 4:A1, 4:A8  
 Venning, M. C., 593  
 Vezzoli, G., 490  
 Videen, J., 897  
 Vogel, F. E., 4:A4, 4:A11  
 Voss, E., 399  
 Wadhwa, N., 712  
 Wagner, L., 4:A3, 4:A14  
 Waiser, J., 871  
 Waite, N. M., 763  
 Waldo, F. B., 817  
 Walker, A., 4:A2, 4:A11  
 Walker, P. D., 465  
 Walser, M., 503  
 Walshe, J. J., 942  
 Wang, S.-R., 888  
 Wang, Y., 601  
 Warnock, D. G., 793  
 Watterson, M. K., 624  
 Webster, N., 763  
 Weinberg, E. P., 362  
 Weir, M. R., 739, 800  
 Weissgarten, J., 230  
 Welshman, I., 907  
 Whittmann, I., 4:A3, 4:A13  
 Williams, A. W., 576  
 Wilson, C. H., 729  
 Wilson, R. F., 601  
 Windus, D. W., 560  
 Wolf, G., 153  
 Wombolt, D., 66  
 Woodward, R. S., 428  
 Wortley, P., 207  
 Wyatt, R. J., 817  
 Yager, H., 4:A3, 4:A7  
 Yamaguchi, S., 345  
 Yamaguchi, T., 435  
 Yamakido, M., 919  
 Yamase, H., 4:A3, 4:A5  
 Yen, T. S. B., 754  
 Yoon, S., 739  
 Yorgin, P., 136  
 Yorioka, N., 919  
 Youngner, S. J., 410  
 Yu, A. S. L., 453  
 Yu, A. W. Y., 91  
 Yu, W., 4:A2, 4:A20  
 Yutani, C., 733  
 Zager, R., 4:A1, 4:A12  
 Zarrabi, M. H., 449  
 Zent, R., 200  
 Zerbi, S., 490  
 Zheng, Y. P., 4:A3, 4:A7  
 Zilahi, Zs., 4:A2, 4:A15  
 Ziyadeh, F. N., 153  
 Zoja, C., 254  
 Zrinyi, M., 4:A2, 4:A21

## SUBJECT INDEX

**Page references to clinical nephrology meetings abstracts in journal number 4 are preceded by 4:A.**

**Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and the page number(s).**

Ab(s), *see* Antibodies  
 Abdominal adiposity, role of insulin resistance and, in dyslipidemia of CRF, 54-65  
 ABPM, *see* Ambulatory blood pressure monitoring  
 Abstracts of sixth annual spring clinical nephrology meetings (April 17-20, 1997), 4:A1-A21  
 ACE, *see* Angiotensin-converting enzyme genotype; Angiotensin-converting enzyme inhibitor(s)  
 Acid-base balance concept  
 chronic metabolic acidosis and, 292-294  
*see also* pH  
 Acid signaling in chronic metabolic acidosis, 298-299  
 Acidosis  
 tubular, classification of, 136-146  
*see also* Metabolic acidosis  
 Acquired immunodeficiency syndrome, *see* Human immunodeficiency virus-associated nephropathy; Human immunodeficiency virus infection  
 ACTH (corticotropin; adrenocorticotrophic hormone) in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513  
 Acute allograft rejection, IL-8 expression following renal transplantation and, 871-880  
 Acute peritonitis on CAPD, NO pathway and amino acids in, 712-719  
 Acute-phase response, and albumin concentrations in ESRD patients on HD, 658-668  
 Acute renal failure (ARF)

due to postinfectious GN during pregnancy, 273-279  
*see also* Acute renal failure, management and outcome of;  
 Oxidants in toxic ARF

Acute renal failure (ARF), management and outcome of, 793-799

- adjunctive agents in, 794-795
- dialysis for, *see* Dialysis for ARF
- future directions in, 798-799
- nephrotoxin avoidance in, 795-796
- nutritional support in, 795
- role of hemodynamic monitoring in, 794

Acute respiratory distress in heparin-induced thrombocytopenia and thrombosis, 449-452

Acute tubular necrosis, acute allograft rejection and, and IL-8 expression following renal transplantation, 871-880

Adaptations to chronic renal ischemia, 170

Adenocarcinoma due to chronic lithium ingestion, 4:A3, 4:A5

Adenoma due to chronic lithium ingestion, 4:A3, 4:A5

Adenosine diphosphate (ADP), and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563

Adhesion molecules

- glomerulointerstitial interaction of, in IgAN and MPGN, 843-850
- role of, in monocyte and granulocyte adherence to human saphenous vein endothelial cells during HD, 78-85

Adiposity, abdominal, role of insulin resistance and, in dyslipidemia of CRF, 54-65

Adjunctive drugs in ARF management, 794-795

Administrative issues related to management of IgAN renal biopsy data, 823-824

ADP (adenosine diphosphate), and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563

ADPKD, *see* Autosomal dominant polycystic kidney disease

Adrenocorticotrophic hormone (ACTH; corticotropin) in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513

Advanced secondary hyperparathyroidism (HPT), calcitriol effects on, 4:A1, 4:A6-A7

Adverse effects

- of chronic lisinopril and fosinopril therapy, 901
- of Na ramping in HD, 669-678
- see also* specific therapeutic modalities

African American(s), *see* Race and ethnicity

African-American Study of Kidney Disease and Hypertension, 720-728

Age

- of ANCA-associated vasculitis patients, 97
- of arteriolar sclerosis patients, 914
- and attitudes toward financial incentives for kidney donation, 412, 414
- of children with biliary atresia, 189
- of CRF and/or ESRD patients, *see* Age of CRF and/or ESRD patients
- of FSGS patients with NS in CAE, 336
- of hypertensive patients, *see* Age of hypertensive patients of ICGN patients with HIV and HCV infections, 516
- of IgAN patients, 528, 530, 833
- of IMN patients, 201
- of membranous nephropathy patients, 116

of myocardial infarction patients with renal artery stenosis, 734

and nephrotic syndrome patients with hematuria and renal insufficiency, 806-810

of NIDDM patients, 908

of preeclamptic nephropathy patients, 347

of renal physicians, 783, 785, 789

of renal transplant recipients, *see* Age of renal transplant recipients

SLC, albuminuria and, 47

of SLE patients, 357

and vasectomy as risk factor for urolithiasis, 208, 209

*see also* Children; Elderly, the; High-school students; Young African Americans

Age of CRF and/or ESRD patients

- on dialysis, reproductive and gynecologic issues and, 686; *see also* Age of CRF and/or ESRD patients on CAPD and/or HD
- and effects of ketoconazole plus low-dose prednisone on CRF progression, 505
- with lupus nephritis, 731
- in MDRD study, 891, 894

Age of CRF and/or ESRD patients on CAPD and/or HD

- ABPM and, 594, 679
- and dialysate Na effects on hypertension, 384
- with dyslipidemic CRF, 55
- and effects of exit-site povidone-iodine ointment on infections, 764
- as factor influencing Ab response to HBV vaccine, 239-245
- with HIVAN, 550
- with HPT, 863, 864
- with hyperphosphatemic CRF, 68
- on in-center HD, 854, 856
- on nifedipine therapy, 234
- positive for HCV, 610, 611
- and preservation of residual renal function, 578
- and quality of life 3 months after start of chronic HD and/or PD, 586, 589
- and resistance to rHuEPO, 566
- starting dialysis, early death and, 217, 219

Age of hypertensive patients

- endogenous EPO and, 377
- on HD, dialysate Na effects, 384
- of hospitalized hypertensive and diabetic patients, 370
- and racial differences in effects of antihypertensive therapy, 723
- renal allograft survival and, 420, 423

Age of renal transplant recipients

- diabetic, atherosclerotic vascular complications and, 602
- hypertensive, renal allograft survival and, 420, 423
- of inner-city recipients, 882
- of long-term recipients, high-bone turnover and HPT and, 747, 749, 750
- positive for HCV, 610, 611

AGT (alanine:glyoxylate aminotransferase), deficiency of, in PH1, 36-44

AIDS (acquired immunodeficiency syndrome), *see* Human immunodeficiency virus-associated nephropathy; Human immunodeficiency virus infection

Air embolism, paradoxical cerebral, due to central venous catheter, 453-455

Al (aluminum)  
in ESRD with HPT, 863, 864  
*see also* Serum aluminum in CRF and/or ESRD

Alanine:glyoxylate aminotransferase (AGT), deficiency of, in PH1, 36-44

Alanine transaminase (ALT; serum glutamate pyruvate transaminase; SGPT)  
in ARF due to postinfectious GN during pregnancy, 274  
in children with biliary atresia, 189  
in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
in ICGN with HIV and HCV infections, 516

Albumin  
in ascitic patients, 394, 395  
in ESRD with HPT, 863, 864; *see also* Albumin in CRF and/or ESRD patients on CAPD and/or HD

and/or ESRD patients on CAPD and/or HD  
postural hemodilution in nephrotic edema and, 628

serum, *see* Serum albumin  
*see also* Albuminuria; Hypoalbuminemia

Albumin in CRF and/or ESRD patients on CAPD and/or HD, 57, 505

and Ab response to HBV vaccine, 240  
before and after CAPD, 695, 696  
concentration of, 658-668  
starting dialysis, 216

Albuminuria  
SLC associated with insulin resistance and, race and, 45-53  
*see also* Proteinuria

Aldosterone  
ACE inhibitor effects on, 4:A2, 4:A20-A21  
postural hemodilution in nephrotic edema and, 628

Alkali, bone, release of, in metabolic acidosis, 297-298

Alkaline phosphatase (ALP)  
in ARF due to postinfectious GN during pregnancy, 274  
in children with biliary atresia, 189  
following parathyroidectomy for secondary HPT in HD patients, 760

Alkaline urine, PCO<sub>2</sub> in, in tubular acidosis, 138-139

Alkalosis, hypokalemic metabolic, with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114

Alleles in HD patients having received HBV vaccine, 242

Allograft, *see* Renal transplantation

ALP, *see* Alkaline phosphatase

Alpha (α)-interferon for fibrillary GN associated with HCV infection, 132-135

ALT, *see* Alanine transaminase

Aluminum, *see* Al

AMA (American Medical Association) Physician Masterfile, 781-782

Ambulatory blood pressure monitoring (ABPM)  
of hypertensive patients, 377, 386  
*see also* Ambulatory blood pressure monitoring in CAPD patients

Ambulatory blood pressure monitoring (ABPM) in CAPD patients, 678-684  
and in HD patients and in renal transplant recipients, 593-600

Amenorrhea in ESRD patients on dialysis, 685-690

American Medical Association (AMA) Physician Masterfile and, 781-782

Amino acid(s)  
NO pathway and, in acute peritonitis on CAPD, 712-719

urinary excretion of, in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Aminoaciduria in nonacidotic proximal tubulopathy with hypercalciuria, 493

Aminotransferase  
deficiency in alanine:glyoxylate, in PH1, 36-44  
*see also* Alanine transaminase; Aspartate transaminase

Amlodipine, short-term effects of, on GFR in hypertensive nephrosclerosis, 720-728

Ammonia, *see* NH<sub>3</sub>

Ammonium, *see* NH<sub>4</sub>

Amoxicillin, proton-pump inhibitor and, in eradication of *H pylori* in dialysis patients with ESRD, 86-90

Amputation in diabetic renal transplant candidates, 601-607

Amyloid A, serum, and albumin concentrations in ESRD patients on HD, 658-668

Amyloidosis, primary, syncope with, 4:A3, 4:A18

Anatomic correlates of IRD, 168-169

ANCA, *see* Antineutrophil cytoplasmic antibodies following renal transplantation; Perinuclear antineutrophil cytoplasmic antibodies

Androgens, effects of, on serum lipid levels, in chronic HD patients, 569-575

Anemia  
in children with biliary atresia, 189  
therapy of, *see* Recombinant human erythropoietin

Angiographic studies of atherosclerotic RAS, 172-173

Angioplasty, *see* Percutaneous transluminal renal angioplasty

Angiotensin II (AII)  
in diabetic nephropathy, 153-163

lisinopril as inhibitor of, in membranous nephropathy, 254-264

Angiotensin-converting enzyme (ACE) genotype, IgAN prognosis and, 819

Angiotensin-converting enzyme (ACE) inhibitor(s)  
antiproteinuric effects of, 801, 803-805  
as AII antagonist in diabetic nephropathy, 153-163

Ca channel blockers and, 801

effects of, on K and aldosterone, 4:A2, 4:A20-A21

enalapril as, *see* Enalapril

fosinopril as, chronic therapy of chronic renal insufficiency with, in older hypertensive patients, racial differences in renal response to, 897-906

for hospitalized hypertensive and diabetic patients, 368-375

in hypertensive nephrosclerosis, short-term effects of, on GFR, 720-728

lisinopril as, *see* Lisinopril

Anions, urinary excretion of, in tubular acidosis, 140

ANP (atrial natriuretic peptide), postural hemodilution in nephrotic edema and, 628

Antibiotics  
effects of, on degradation of Cr in CRF, 72-77  
for *Xanthomonas maltophilia*, 93  
*see also* specific antibiotics

Antibodies (Abs)  
antineutrophil cytoplasmic, *see* Antineutrophil cytoplasmic antibodies following renal transplantation

antiphospholipid, in pediatric SLE, 355-361

antipodocyte and anti-brush border, in familial idiopathic membranous nephropathy, 115-118

factors influencing response of, to HBV vaccine in HD patients, 239-245

Anti-brush border antibodies in familial idiopathic membranous nephropathy, 115-118

Antigen(s)

- cancer antigen 125 and dialysate cell population in stable CAPD patients, peritoneal transport parameters and, 699-705
- see also* HLAs

Antihypertensive therapy

- effectiveness of, 4:A2, 4:A17
- effects of, on GFR, race and, 720-728
- see also specific antihypertensive agents; for example:* Angiotensin-converting enzyme inhibitor(s); Ca channel blocker(s)

Antineutrophil cytoplasmic antibodies (ANCA) following renal transplantation

- IgA, recurrence of IgAN with, 125-131
- outcome of vasculitis associated with, 96-102
- see also* Perinuclear antineutrophil cytoplasmic antibodies

Antinuclear factor in membranous nephropathy, 116

Anti-oxygen ( $O_2$ ) free radicals, tea polyphenol, for CRF, 4:A3, 4:A7

Antiphospholipid antibodies (aPLs) in pediatric SLE, 355-361

Antipodocyte antibodies in familial idiopathic membranous nephropathy, 115-118

Antiproteinuric effects of Ca channel blockers, influence of dietary NaCl on, 800-805

Apheresis, pseudopulmonary embolism in heparin-induced thrombocytopenia and, 449-452

aPLs (antiphospholipid antibodies) in pediatric SLE, 355-361

Apolipoproteins

- in CRF, 57
- and nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575

Apoptosis in PKD, paclitaxel effects on, 435-444

Appetite of ESRD patients on CAPD and after renal transplantation, changes in, 691-698

ARF, *see* Acute renal failure

Arginine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

L-arginine, depletion of, in acute peritonitis on CAPD, 712-719

Arteriolar hyalinosis in proteinuric GN, 30, 31

Arteriolar sclerosis, myofibroblasts and, in diabetic nephropathy, 912-918

Arteriovenous access, *see* Peripheral arteriovenous versus central venous vascular access

Arteriovenous (AV) disequilibrium in peripheral AV versus CVV access

cardiopulmonary recirculation, dialysis delivery and, 483-484

defined, 488

Arteriovenous (AV) fistula

- percutaneous mechanical thrombectomy in salvage of, 4:A1, 4:A9
- pulse oxymetry of  $O_2$  saturation in upper extremity with, before and after HD, 230-232

Arthritis, rheumatoid, in relatives of lupus nephritis patients, 731

Ascites in children with biliary atresia, 189

Ascitic fluid reinfusion, concentrated, in cirrhosis, 392-398

Aspartate transaminase (AST; SGOT)

- in ARF due to postinfectious GN during pregnancy, 274
- in HCV infections, *see* Aspartate transaminase in HCV infection
- in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Aspartate transaminase (AST; SGOT) in HCV infection

- in ESRD patients, 610, 611
- in ICGN with HIV and HCV infections, 516

Aspirin, effects of ticlopidine and, on platelet deposition on PTFE graft fistulas, 560-564

Associated conditions, *see* Comorbidity in CRF and/or ESRD patients

AST, *see* Aspartate transaminase

Atenolol, short-term effects of, on GFR in hypertensive nephrosclerosis, 720-728

Atheroembolism, cholesterol, FSGS with NS in, 334-344

Atherosclerotic renal artery stenosis, *see* Renal artery stenosis

Atherosclerotic vascular complications in diabetic renal transplant recipients, 601-607

Atresia, biliary, elevated HGF in children with, 188-192

Atrial natriuretic peptide (ANP), postural hemodilution in nephrotic edema and, 628

Attitudes of patients toward financial incentives for kidney donation, 410-418

AII, *see* Angiotensin II

Autosomal dominant liver disease, portal hypertension and bleeding esophageal varices with, 4:A3, 4:A18

Autosomal dominant nonacidotic proximal tubulopathy, 490-495

Autosomal dominant polycystic kidney disease (ADPKD) portal hypertension and bleeding esophageal varices with, 4:A3, 4:A18

sex and effects of gonadal hormones on progression of, 265-272

AV, *see entries beginning with term:* Arteriovenous

Azotemia in ADPKD, 265-272

B cells, effects of nifedipine discontinuation on cytosolic Ca and proliferation of, in CRF patients on HD, 233-238

Bacterial toxins, renal disorders due to, ETs in, 14

Beneficial effects of Na ramping in HD, 669-678

Berger's disease, *see* IgA nephropathy

BF, *see* Blood flow, vascular access; Renal blood flow

Bicarbonate, *see*  $HCO_3$

Bicarbonaturia in renal tubular acidosis, 137-138, 141, 144

Bilateral renal artery stenosis (RAS) in IRD, 173; *see also* Ischemic renal disease

Bilateral renal vein thrombosis (RVVT), proteinuria secondary to, systemic thrombolytic therapy of, 615-619

Biliary atresia, elevated HGF in children with, 188-192

Bilirubin in ARF due to postinfectious GN during pregnancy, 274

Biochemistry

- following parathyroidectomy for secondary HPT in HD patients, 759-762
- of mesangial cell contraction, 973-974

*see also specific biochemical data*

Biocompatibility of glucose polymer-containing PDFs, 246-253

Bioelectrical impedance analysis of nephrotic edema, 627-630

Biology of ETs, *see* Endothelin biology

Biopsy, *see* Renal biopsy

Birth control, sexual activity and, in ESRD women on dialysis, 687

Bleeding esophageal varices, portal hypertension and, due to ADPKD, 4:A2, 4:A18

Blood alterations in IgA nephropathy, 4:A3, 4:A14

Blood flow (BF), vascular access

relationship of recirculation to, 223-229

*see also* Blood flow in peripheral AV versus CVV access

Blood flow (BF) in peripheral AV versus CVV access, 484-487

dialyzer and, 486-487

*see also* Regional blood flow model in peripheral AV versus CVV access

Blood pressure (BP)

ambulatory, *see* Ambulatory blood pressure monitoring of ascitic patients, 394

dietary salt, proteinuria and, 800-803, 805

epidemiological data of high-school students', 4:A2, 4:A15

in ESRD, *see* Blood pressure in CRF and/or ESRD with IgAN, 530

in IMN, 201, 202

of membranous nephropathy patients on lisinopril therapy, 257

Na ramping effects on, in HD, 673

in preeclampsia, 347

*see also* Hypertension; Hypotension

Blood pressure (BP) in CRF and/or ESRD, 578

effects of multidisciplinary predialysis interventions on, 536

in hyperphosphatemic CRF, 68

quality of life and, 891

rHuEPO effects on, in predialysis patients, 543-545

Blood urea, and vascular access BF, 224

Blood urea nitrogen, *see* BUN

BMI, *see* Body mass index

Body mass index (BMI)

of CRF and/or ESRD patients, 55, 567, 695, 696

of hypertensive patients, 377, 420, 423, 723

of NIDDM patients, 908

of renal transplant recipients, 420, 423, 747, 749

SLC, albuminuria and, 47, 49, 50

Body weight (BW)

of ADPKD subjects, 267, 268

of CRF and/or ESRD patients, 68, 543, 695, 696

of hypertensive patients, 377, 420

of membranous nephropathy patients on lisinopril therapy, 257

Na ramping in HD and gain in, 671-673

sex and, and nephrosclerosis, 4:A4, 4:A16

SLC, albuminuria and, 47

Bone alkali, release of, in chronic metabolic acidosis, 297-298

Bone density

with reduced renal function, 4:A3, 4:A9

rHuEPO effects on, 4:A2, 4:A11-A12

Bone disease

hyperparathyroid, calcitriol therapy of, 646-647

low-turnover, calcitonin effects in dialysis patients with, 4:A2, 4:A19

nonacidotic proximal tubulopathy and, 493

Bone metabolism with reduced renal function, 4:A3, 4:A9

Bone turnover

high-, HPT and, in normocalcemic long-term renal transplant recipients, 746-753

low-, bone disease with, calcitonin effects in dialysis patients with, 4:A2, 4:A19

Bowel

severe hyperphosphatemia following phosphate administration for preparation of, in renal failure patients, 103-105

*see also* Short bowel syndrome and entries beginning with term: Intestinal

BP, *see* Blood pressure

Brequinar sodium, 310

BUN (blood urea nitrogen)

in hospitalized hypertensive and diabetic patients, 370

in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

serum, in ARF due to postinfectious GN during pregnancy, 274

BW, *see* Body weight

Ca (calcium)

in CRF and/or ESRD, *see* Ca in CRF and/or ESRD

dietary, *see* Dietary Ca

in glucose polymer-containing PDFs, 247

in hypokalemic metabolic alkalosis with hypomagnesuria

hypermagnesemia and severe hypocalciuria, 108

hypophosphatemia, *see* Ca, hypophosphatemia and total, *see* Total Ca

*see also* Ca channel blocker(s); Calciuria; Hypercalcemia; Hypocalcemia and entries beginning with terms: Non-calcemic, Normocalcemic

Ca (calcium), hypophosphatemia and

in multiple myeloma with hyperphosphaturia and hypophosphatemia, 446

P-enriched conventional Ca-containing dialysis solution for hypercalcemia and hypophosphatemia with HPT, 288-290

Ca (calcium) channel blocker(s) (CCBs)

antiproteinuric effects of, influence of dietary NaCl on, 800-805

felodipine as, for hypertension with impaired cognitive function, MRI evidence of white matter, and multi-infarct disease, 4:A2, 4:A9

nifedipine as, effects of discontinuation of, on cytosolic Ca, and B cell proliferation in CRF patients on HD, 233-238

Ca (calcium) in CRF and/or ESRD

cytosolic, effects of nifedipine discontinuation on B cell proliferation and, in CRF patients on HD, 233-238

dietary, *see* Dietary Ca for HPT in CRF and/or ESRD patients

effects of multidisciplinary predialysis interventions on, 536

with HPT, 863, 864  
*see also* Ca and phosphate metabolism management in CRF and/or ESRD

Ca (calcium) and phosphate metabolism management in CRF and/or ESRD, 641-649

Ca metabolism in ESRD, 642-644

Ca metabolism in normal subjects, 641-642

phosphate metabolism in ESRD, 644-645

proposed, 646

soft tissue calcification due to Ca and phosphate overload and, 645-646

therapy of secondary HPT and hyperparathyroid bone disease with calcitriol and, 646-647

Ca<sub>2</sub>O<sub>4</sub> (calcium oxalate) in PHI, 36-44

CAD, *see* Coronary artery disease

CAE (cholesterol atheroembolism), FSGS with NS in, 334-344

Calcification, soft tissue, due to Ca and phosphate overload in ESRD, 645-646

Calciphylaxis in Crohn's disease without ESRD, 773-776

Calcitonin, effects of, in dialysis patients with low-turnover bone disease, 4:A2, 4:A19

Calcitriol [1,25-dihydroxyvitamin D<sub>3</sub>; 1,25-(OH<sub>2</sub>)D<sub>3</sub>] effects of, on intestinal Ca absorption, 642

plasma, in nonacidotic proximal tubulopathy with hypercalcemia, 493

response to HBV vaccine and, 240

for secondary HPT, *see* Calcitriol for secondary HPT

serum, in long-term renal transplant recipients, 747, 749

Calcitriol [1,25-dihydroxyvitamin D<sub>3</sub>; 1,25-(OH<sub>2</sub>)D<sub>3</sub>] for secondary HPT

with bone disease, 646-647

with CRF, 496-502

pulse, for advanced secondary HPT patients on HD, 4:A1, 4:A6-A7

Calcium, *see* Ca

Calcium oxalate (CaC<sub>2</sub>O<sub>4</sub>) in PHI, 36-44

Calciuria

hypercalciuria in nonacidotic proximal tubulopathy, 490-495

in nonacidotic proximal tubulopathy, 493

severe hypocalciuria with hypokalemic metabolic alkalosis and hypomagnesuric hypermagnesemia, 106-114

Calculi, *see* Nephrolithiasis; Urolithiasis

Cancer, *see* Multiple myeloma; Renal transplantation in patients with malignant disease

Cancer antigen 125, dialysis cell population and, in stable CAPD patients, peritoneal transport parameters and, 699-705

CAPD, *see* Continuous ambulatory peritoneal dialysis

Capillary-mesangial biomechanical unit in GFR regulation, 972

Carbon dioxide partial pressure (PCO<sub>2</sub>) in alkaline urine in tubular acidosis, 138-139, 141

Carbonic anhydrase II deficiency, HCMA and, 143-144

Cardiac troponin I (cTnI) and cardiac troponin T (cTnT), serum, and prognosis of chronic HD patients, 399-403

Cardiopulmonary recirculation in peripheral AV versus CVV access

AV disequilibrium, dialysis delivery and, 483-484

defined, 488

Cardiovascular (CV) risk factors on dialysis for CRF and/or ESRD, 4:A2, 4:A13

Cardiovascular (CV) system

rHuEPO effects on, in predialysis CRF patients, 541-548

*see also* Heart rate entries beginning with terms: Myocardial, Venous, Ventricular and elements: Arteri-, Card-, Vascu-

Catalytic Fe (iron), cytochrome P-450 as source of, in myoglobinuric ARF, 471-472

Catheters

infected, *see* Exit-site infections, catheter; Tunnel infections

recirculation and type of, 480, 483

*see also* Long-term vascular access for HD, catheters for; Venous catheters

CCBs, *see* Ca channel blocker(s)

Cell population, cancer antigen 125 and dialysate, in stable CAPD patients, peritoneal transport parameters and, 699-705

Cell proliferation, excessive, glomerular diseases with ECM accumulation, fibrosis and, ETs in, 14-15

Cellulose acetate dialyzers, preservation of residual renal function with PS and/or, in ESRD patients on CAPD, compared, 576-583

Central venous catheters, paradoxical cerebral air embolism due to, 453-455

Central venous (CVV) access, *see* Peripheral arteriovenous versus central venous vascular access

Central venous (CVV) catheters, recirculation with, 483

Cerebral air embolism, paradoxical, due to central venous catheter, 453-455

Cerebrovascular accidents (CVAs) in diabetic renal transplant candidates, 601-607

C4bp, PS and, 931-935

CGN, *see* Crescentic glomerulonephritis

Chemotherapy of fMF with light chain deposition disease, 942-946

Children

with biliary atresia, elevated HGF in, 188-192

with SLE, aPLs in, 355-361

Chloride, *see* Cl

Cholesterol

in CRF, *see* Cholesterol in CRF

hypercholesterolemia, myocardial infarction, and renal artery stenosis, 734

total, in diabetic renal transplant candidates, 602

*see also* Lipids

Cholesterol atheroembolism (CAE), FSGS with NS in, 334-344

Cholesterol in CRF, 57

effects of RenaGel on, in hyperphosphatemic CRF, 66-71

Chronic fosinopril and/or lisinopril therapy in older hypertensive patients with chronic renal insufficiency, racial differences in renal response to, 897-906

Chronic glomerulopathy, CRF and, 505, 507

Chronic hemodialysis (HD)

for ESRD, *see* Chronic hemodialysis for CRF and/or ESRD

nandrolone decanoate effects on serum Lp(a) concentrations in patients on, 569-575

serum cardiac troponin I and cardiac troponin T and prognosis of patients on, 399-403

Chronic hemodialysis (HD) for CRF and/or ESRD  
enalapril-rHuEPO interaction in patients on, 4:A2, 4:A18  
quality of life 3 months after start of, 584-592  
rehabilitation of patients on, 4:A2, 4:A21  
withdrawal from, 4:A2, 4:A20

Chronic interstitial nephritis, ESRD and, 653

Chronic metabolic acidosis, 291-302  
acid-base balance concept and, 292-294  
defined, 291-292  
homeostatic response to, 294-300  
therapy of, 300

Chronic pyelonephritis, ESRD and, 660

Chronic renal failure (CRF)  
anemia of, *see* Recombinant human erythropoietin for CRF  
and/or ESRD patients on CAPD and/or HD  
anti-oxygen free radicals of tea polyphenols for, 4:A3, 4:A7  
creatininase activity induction in, 72-77  
diabetic, *see* Diabetic chronic renal failure and/or end-stage renal disease  
dialysis for, *see* Dialysis for CRF and/or ESRD  
dyslipidemia of, role of abdominal adiposity and insulin resistance in, 54-65  
ET-1 in, 16-17  
nutrition in, *see* Chronic renal failure, nutrition in progression of, and to, *see* Progression of (and to) CRF and/or ESRD  
RenaGel as noncalcemic phosphate binder for hyperphosphatemia in, 66-71  
secondary HPT with, dietary P and Ca in, 496-502  
*see also* End-stage renal disease

Chronic renal failure (CRF), nutrition in  
hypoalbuminemia and, 658-668  
MDRD study of quality of life in, 888-896  
metabolic acidosis influence on nutrition, 5:xlvii-xlviii

Chronic renal insufficiency in the elderly  
with hypertension, chronic lisinopril and/or fosinopril therapy of, racial differences in renal response to, 897-906  
IMN and, 203

Chronic renal ischemia, adaptations to, 170

Chronic vascular disease/GGS in FSGS with NS, 339

Cirrhosis, concentrated ascitic fluid reinfusions in, 392-398

Citrate  
tubular absorption of, in chronic metabolic acidosis, 294-296  
urinary excretion of, in tubular acidosis, 140, 141

Citrulline in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

CK-MB (creatine kinase MB), and myocardial injury diagnosis in chronic HD patients, 399-403

Cl (chloride)  
dietary Na, influence of, on antiproteinuric effects of Ca channel blockers, 800-805  
in glucose polymer-containing PDFs, 247  
in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
in hypokalemic metabolic alkalosis with hypomagnesuria hypermagnesemia and severe hypocalciuria, 108  
postural hemodilution in nephrotic edema and, 628  
serum, *see* Serum Cl

Classification  
of FSGS with NS in CAE, 337-338  
histologic IgAN subclassification, 829-842  
of tubular acidosis, 136-146

Clinical course  
of ICGN with HIV and HCV infections, 516  
of IgAN and MPGN, ICAM1, ICAM3, and LFA1 interstitial expression and, 846-847  
of relapsing NS, 967  
*see also entries beginning with term:* Progression

Clinical features and presentation  
of ANCA-associated vasculitis patients, 97  
of FSGS with NS in CAE, 336-337  
of ICGN with HCV and HIV infections, 515-516  
of IgAN, 528  
of IRD, 175-176  
of primary amyloidosis with syncope, 4:A3, 4:A18  
*see also* Symptom(s) and specific conditions

Clinical studies and trials of new immunosuppressive agent(s), 303-312  
of brequinat sodium, 310  
of costimulatory signals and fusion proteins, 311  
of CsA, 304-305  
of CsG, 305  
of 15-deoxyspergualin, 310-311  
of FK-506, 305-307  
of HLA-derived peptides, 311-312  
of leflunomide, 308  
of mizoribine, 308-309  
of mycophenolate mofetil, 309-310  
of rapamycin, 307  
of SKF-105685, 311

Clinicopathologic correlations from IgAN database of Mayo Nephrology Collaborative Group, 820-821

CMV (cytomegalovirus) infection, effects of, on renal allograft and patient survival, 428-434

CO<sub>2</sub> (carbon dioxide)  
effects of P-enriched conventional Ca-containing dialysis solution on, 289  
partial pressure, in tubular acidosis, 138-139, 141  
total, ARF due to postinfectious nephritis in pregnancy, 274

Cognitive function, felodipine for hypertension with MRI evidence of white matter, multi-infarct disease, and impaired, 4:A2, 4:A9

Collagen, and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563

Collagen III in arteriolar sclerosis, 912-918

Collagen mRNA (messenger ribonucleic acid), skin fibroblast, in IDDM nephropathy patients, 4:A4, 4:A20

Collapsing glomerulopathy with IC deposits, HIV and HCV infections and, 519-520

Collecting duct, inner medullary, fluid and electrolyte transport by, ET effects on, 8-10

Communication, computerized, in vascular access management, 4:A2, 4:A18-A19

Comorbidity in CRF and/or ESRD patients  
and quality of life 3 months after start of chronic HD and/or PD, 586, 588, 589  
starting dialysis, early death and, 214-222  
*see also* specific conditions

Compartmental volume loss during HD, 4:A1, 4:A11

Complement, *see* C4bp; C1q nephropathy

Computerized communication in vascular access management, 4:A2, 4:A18-A19

Concentrated ascitic fluid reinfusion in cirrhosis, 392-398

C1q nephropathy, relapsing NS, minimal change NS, FSGS and, 966-970

Constrictive perinephritis (Page kidney), hypertension secondary, 620-623

Continuous ambulatory peritoneal dialysis (CAPD)

- ABPM in patients on, *see* Ambulatory blood pressure monitoring in CAPD patients
- for CRF and/or ESRD, *see* Continuous ambulatory peritoneal dialysis for CRF and/or ESRD
- dialysate cell population and cancer antigen 125 in stable patients on, peritoneal transport parameters and, 699-705
- peritonitis on, *see* Peritonitis on CAPD

Continuous ambulatory peritoneal dialysis (CAPD) for CRF and/or ESRD

Ca and phosphate metabolism in, *see* Ca and phosphate metabolism management in CRF and/or ESRD

changes in eating behavior on, and after renal transplantation, 691-698

HHD for patients trained in self-care, 4:A1, 4:A10

preservation of residual renal function with PS and/or cellulose acetate membrane dialyzers in, compared, 576-583

*see also* Dialysis for CRF and/or ESRD

Continuous renal replacement therapy (CRRT) for ARF, 796

Conventional Ca (calcium)-containing dialysis solution, P-enriched, HD with, for hypercalcemia and hypophosphatemia with HPT, 288-290

Coronary artery disease (CAD)

- in diabetic renal transplant candidates, 601-607
- renal artery stenosis and, 733-738

Cortical membranes, effects of K depletion on lipids and protein of, 4:A4, 4:A8-A9

Cortical mitochondria, *see* Renal cortical mitochondria

Corticosteroids

- effects of, on lymphocytes in primary GN, 4:A3, 4:A17
- long-term therapy of HIVAN with, 624-626
- see also specific corticosteroids*

Corticotropin (ACTH; adrenocorticotrophic hormone) in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513

Cortisol in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513

Cost-effectiveness of anemia screening prior to starting rHuEPO therapy of ESRD patients, 651-657

Costimulatory signals, fusion proteins and, in immunosuppression, 311

Country of graduation of renal physicians, 783, 785, 787, 789

Cr, *see* Creatinine and creatinine clearance

C-reactive protein (CRP) in CRF and/or ESRD patients on HD

- albumin concentrations and, 658-668
- as predictor of resistance to rHuEPO, 565-568

Creatine kinase MB (CK-MB), and myocardial injury diagnosis in chronic HD patients, 399-403

Creatininase, induction of activity of, in CRF, 72-77

Creatinine (Cr) and creatinine (Cr) clearance

- in ascitic patients, 394
- in CRF and/or ESRD, *see* Creatinine and creatinine clearance in CRF and/or ESRD
- in hospitalized hypertensive and diabetic patients, 370
- in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- in hypokalemic metabolic alkalosis with hypomagnesuria and hypomagnesemia and severe hypocalciuria, 108
- in IgAN, 530
- in long-term renal transplant recipients, high-bone turnover and HPT in, 747, 749
- in membranous nephropathy, 116
- in NIDDM, 908
- plasma, in ascitic patients, 394
- postural hemodilution in nephrotic edema and, 628
- serum, *see* Serum creatinine
- SLC, albuminuria and, 49

Creatinine (Cr) and creatinine (Cr) clearance in CRF and/or ESRD

- before and after CAPD, 695
- effects of antibiotics on degradation of, 72-77
- effects of multidisciplinary predialysis interventions on, 536
- in IMN, 202, 203
- and rHuEPO therapy in predialysis patients, 543
- with secondary HPT, 496

Crescentic glomerulonephritis (CGN)

- IgAN and, 528
- necrotizing, ANCA-associated vasculitis and, 96-102

CRF, *see* Chronic renal failure

Critical renal perfusion pressure, IRD and, 169

Crohn's disease, calciphylaxis in, without ESRD, 773-776

CRP, *see* C-reactive protein in CRF and/or ESRD patients on HD

CRRT (continuous renal replacement therapy) for ARF, 796

Cryoglobulinemia in ICGN patients with HIV and HCV infections, 516

CsA, *see* Cyclosporin A

CsG (cyclosporin G; OG37-325), 305

cTnI (cardiac troponin I) and cTnT (cardiac troponin T), serum, and prognosis of chronic HD patients, 399-403

Current supply of renal physicians, 782-784

CV system, *see* Cardiovascular system

CVAs (cerebrovascular accidents) in diabetic renal transplant candidates, 601-607

CVV (venovenous) access, *see* Peripheral arteriovenous versus central venovenous vascular access

Cyclosporin A (CsA)

- clinical trials and studies of, 304-305
- see also* Nephrotoxicity of CsA

Cyclosporin G (CsG; OG37-325), 325

Cyst(s), tubular, due to lithium ingestion, 4:A3, 4:A5

Cystic disease, *see* Autosomal dominant polycystic kidney disease; Autosomal dominant polycystic liver disease; Polycystic kidney disease, CRF and/or ESRD and; Progression of PKD

Cystine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Cytochrome P-450, as source of catalytic Fe in myoglobinuric ARF, 471-472

Cytokines  
and hypoalbuminemia in ESRD patients on HD, 658-668  
and Lp effects on mesangial cell proliferation, 919-930

Cytomegalovirus (CMV) infection, effects of, on renal allograft and patient survival, 428-434

Cytoplasmic antibodies, *see* Antineutrophil cytoplasmic antibodies following renal transplantation

Cytosolic Ca, effects of nifedipine discontinuation on B cell proliferation and, in CRF patients on HD, 233-238

Database development on IgAN biopsy, issues related to, 822-823

DBP (diastolic blood pressure), *see* Blood pressure

Death, *see* Mortality of HD patients

Dehydrogenase, lactate, in ARF due to postinfectious GN during pregnancy, 274

Dense deposit disease, IgAN and, 528

Density of bones, *see* Bone density

Dent's disease, nonacidotic proximal tubulopathy compared with, 493

15-Deoxyspergualin, 310-311

Detection, *see* Diagnosis and detection

Diabetes mellitus (DM)  
in FSGS with NS in CAE, 336  
myocardial infarction, renal artery stenosis and, 734  
as risk factor for presence of atherosclerotic RAS in IRD, 173  
*see also* Diabetic nephropathy; Renal transplantation in diabetic patients

Diabetic chronic renal failure (CRF) and/or end-stage renal disease (ESRD), 412, 414  
and ABPM monitoring in CAPD patients, 679  
in chronic HD patients, residual renal function preservation using polysulfone dialyzers and, 581  
and effects of ketoconazole and low-dose prednisone on CRF progression, 503-513  
with HCV infection, 610, 611  
in HD patients, early death prediction and, 217  
with HPT, 863-864  
with hyperphosphatemia, 68  
hypoalbuminemia and, 658-668  
in in-center HD patients, 854, 856  
NIDDM-related, pharmacokinetics of oral glyburide in, 907-911  
quality of life in, 586, 588  
race and sex as risk factors for, 4:A3, 4:A19-A20

Diabetic nephropathy  
AII in, 153-163  
dialysate Na effects on hypertension in, 384  
due to NIDDM, collagen mRNA in skin fibroblasts, MMP-1, and tissue inhibitor of metalloproteinase-1 in, 4:A4, 4:A20  
due to NIDDM, 4:A3, 4:A13-A14  
early detection and management of hospitalized patients with, 368-375  
effects of exit-site povidone-iodine ointment on infections in, 764  
myofibroblasts and arteriolar sclerosis in, 912-918  
and renal transplantation in inner-city residents, 883

*see also* Diabetic chronic renal failure and/or end-stage renal disease

Diagnosis and detection  
CK-MB and myocardial injury, in chronic HD patients, 399-403  
differential FSGS, 148  
early, of renal disease in hospitalized diabetic and hypertensive patients, 368-375  
of IRD, 176-178  
primary, *see* Primary disease  
of relapsing NS, 967  
*see also* Screening and specific conditions and techniques; *for example*: Renal biopsy

Dialysis cell population, cancer antigen 125 and, in stable CAPD patients, peritoneal transport parameters and, 699-705

Dialysate Na (sodium), effects of, on hypertension, 383-391

Dialysis  
for ARF, *see* Dialysis for ARF  
calcitonin effects in low-turnover bone disease patients on, 4:A2, 4:A19  
for CRF and/or ESRD, *see* Dialysis for CRF and/or ESRD  
initiation of, in multidisciplinary predialysis interventions, 533-540  
pseudopulmonary embolism in heparin-induced thrombocytopenia in patients on, 449-452  
surgical revascularization of dialysis-dependent IRD, 180  
*see also* Dialyzer(s); Hemodialysis; Peritoneal dialysis *entries beginning with terms*: Dialysate, Dialysis, Intradialytic

Dialysis for ARF, 796-797

PD for ARF with HUS, pleural effusion complicating, 4:A1, 4:A6  
urea measuring vascular access recirculation in, 4:A1, 4:A10-A11

Dialysis for CRF and/or ESRD  
amoxicillin and proto-pump inhibitor in eradication of *H. pylori* in patients on, 86-90  
Lp(a) and other cardiovascular risk factors on, 4:A2, 4:A13  
with PS and/or cellulose acetate dialyzers, preservation of renal function with, compared, 576-583  
women on, gynecologic and reproductive issues in, 685-690  
*see also* Continuous ambulatory peritoneal dialysis for CRF and/or ESRD; Dialysis delivery in CRF and/or ESRD; Hemodialysis for CRF and/or ESRD; Peritoneal dialysis for CRF and/or ESRD

Dialysis delivery  
in ARF, 796  
*see also* Dialysis delivery in CRF and/or ESRD

Dialysis delivery in CRF and/or ESRD  
adequacy of, in in-center HD (1993-1995), 851-861  
hypoalbuminemia and, 658-668  
suboptimal, in hospitalized ESRD patients, 4:A2, 4:A14-A15  
*see also* Dialysis delivery with peripheral AV versus CVV access

Dialysis delivery with peripheral AV versus CVV access

Dialysis delivery with peripheral AV versus CVV access, 487-488

AV disequilibrium, cardiopulmonary recirculation and, 483-484

Dialysis fluids and solutions  
 conventional Ca-containing, enriched with P for hypercalcemia and hypophosphatemia with HPT, 288-290  
*see also* Peritoneal dialysis fluids

Dialyzer(s)  
 in ARF dialysis, 796-797  
 BF of, in peripheral AV versus CVV access, 486-487  
 PS and/or cellulose acetate, preservation of residual renal function with, in ESRD patients on CAPD, compared, 576-583

Diastolic blood pressure, *see* Blood pressure

Dietary Ca (calcium)  
 long-term renal transplant recipients' intake of, high-bone turnover and HPT in, 747, 750  
*see also* Dietary Ca for HPT in CRF and/or ESRD patients

Dietary Ca (calcium) for HPT in CRF and/or ESRD patients, 863  
 for secondary HPT, importance of dietary P and, 496-502

Dietary NaCl (sodium chloride), influence of, on antiproteinuric effects of Ca channel blockers, 800-805

Dietary P (phosphorus), importance of dietary Ca and, in secondary HPT with CRF, 496-502

Dietary protein intake  
 by CRF patients, quality of life and, 891  
 effects of, on renal work, historical view of, 777-780

Diethylene triamine pentaacetic acid (DTPA), clearance of, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 109

Differential diagnosis of FSGS, 148

Diffuse progressive glomerulonephritis (DPGN), IgAN and, 528, 530

Diffuse proliferative lupus nephritis (DPLN), PS deficiency and, 931-935

1,25-Dihydroxyvitamin D<sub>3</sub>, *see* Calcitriol

Diphosphate, adenosine, and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563

Disequilibrium, *see* Arteriovenous disequilibrium in peripheral AV versus CVV access; Venovenous disequilibrium in peripheral AV versus CVV access

Distal solute reabsorption, fractional, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesuria and severe hypocalciuria, 106-114

Diuresis  
 need to reduce, renal work concept and, 777-780  
*see also* Urinary excretion

DM, *see* Diabetes mellitus

Donors  
 living, effects of education program for families of renal transplantation candidates on rates of, 739-745  
 opinion polls on ethical problems related to, 4:A4, 4:A10  
 patient attitudes toward financial incentives for kidney donation, 410-418

Dose  
 corticosteroid, *see* Dose, corticosteroid  
 rHuEPO, resistance to rHuEPO and, 567

Dose, corticosteroid  
 and effects on lymphocytes in primary GN, 4:A3, 4:A17  
 ketoconazole and low-dose prednisone effects on progression of CRF, 503-513

DPGN (diffuse progressive glomerulonephritis), IgAN and, 528, 530

DPLN (diffuse proliferative lupus nephritis), PS deficiency and, 931-935

DTPA (diethylene triamine pentaacetic acid), clearance of, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 109

Dual-lumen catheters, silicon, long-term vascular access for HD using, with guidewire replacement of catheters, 553-559

Dysfunctional signaling pathways in mesangial cell regulation of GFR in renal disease, 976-977

Dyslipidemia of CRF, role of abdominal adiposity and insulin resistance in, 54-65

Eating behavior, changes in, of ESRD patients on CAPD and after renal transplantation, 691-698

ECM, *see* Extracellular matrix

Edema, nephrotic, postural hemodilution in, as cause of hemorrhage following renal biopsy, 627-630

Education  
 patient, on multidisciplinary predialysis interventions, 533-540  
 program of, for families of renal transplantation candidates, effects of, on LD rates, 739-745  
*see also* Educational status

Educational status  
 and attitudes toward financial incentives for kidney donation, 412, 414  
 of CRF patients, quality of life and, 891  
 of inner-city renal transplant recipients, 882  
 and quality of life 3 months after start of chronic HD and/or PD, 586, 588  
 and vasectomy as risk factor for urolithiasis, 209

Elderly, the  
 chronic renal insufficiency in, *see* Chronic renal insufficiency in the elderly  
 with IRD, SCr following renal artery angioplasty in, 4:A4, 4:A11  
 therapy of IMN in, 200-206

Electrolytes, *see* Fluid and electrolytes

Electrophoresis, sodium dodecyl sulphate-polyacrylamide gel, proteinuria in GN characterized with, 27-35

Embolism, 449-455  
 FSGS with NS in cholesterol atheroembolism, 334-344  
 paradoxical cerebral air, due to central venous catheter, 453-455  
 pseudopulmonary, in heparin-induced thrombocytopenia and thrombosis, 449-452

Employment status  
 of diabetic renal transplant candidates, 602  
 of HCV-positive ESRD patients, 610  
 and quality of life 3 months after start of chronic HD and/or PD, 588, 589  
 unemployment among inner-city renal transplant recipients, 881-887

Enalapril  
 rHuEPO interaction with, in chronic HD patients, 4:A2, 4:A18  
 short-term effects of, on GFR in hypertensive nephrosclerosis, 720-728

Encapsulating peritonitis, sclerosing, surgery of, 456-460

Endogenous erythropoietin, *see* Erythropoietin

Endothelial cells, human saphenous vein, serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85

Endothelin (ET) biology, 2-26  
future directions in, 17  
general, 2-3  
in kidney, *see* Endothelin biology in kidney

Endothelin (ET) biology in kidney, 3-17  
in glomerulus, 6-7  
in renal disorders, 12-17  
in renal resistance vessels, 4-6  
in renal tubule, 7-11

Endothelin (ET) receptors, 3-5  
general biology of, 3  
in renal tubule, 8  
in renal vasculature, 4-5

Endothelin-1 (ET-1)  
in hypertension, 15-17  
in preeclamptic nephropathy, 345-354  
*see also* Endothelin biology; Glomerular filtration rate, ET-1 and; Renal vasculature, ET-1 in

Endotheliopathy, as continuum of HUS due to MMC therapy, 280-284

End-stage renal disease (ESRD)  
Ca and phosphate metabolism management in, *see* Ca and phosphate metabolism management in CRF and/or ESRD  
calciphylaxis in Crohn's disease without, 773-776  
diabetic, *see* Diabetic chronic renal failure and/or end-stage renal disease  
dialysis for, *see* Dialysis for CRF and/or ESRD  
ET-1 in, 16-17  
following Li therapy, 4:A3, 4:A7  
with HCV infection, renal transplant effects on survival with, 608-614  
IRD and, 175  
multidisciplinary predialysis interventions for, 533-540  
and proteinuric GN, 32-33  
*see also* Chronic renal failure; Recombinant human erythropoietin for CRF and/or ESRD patients on CAPD and/or HD

Entomophthoromycosis, systemic, severe hypertension secondary to, 620-623

Enzymic phenotype, lack of relationship between genotype, severity of PH1 and, 36-44

Epidemiological data  
on high-school students' BP and urine analysis, 4:A2, 4:A15  
*see also* Prevalence

Epithelial cell proliferation in PKD, paclitaxel effects on, 435-444

EPO, *see* Erythropoietin

ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) Registry, 6:xxxii

Erythropoietin (EPO)  
in CAPD and HD patients, and renal transplant recipients, ABPM and, 594  
correlation between hypertension and, 376-382  
in ESRD 3 months after start of chronic HD, 586, 588  
*see also* Recombinant human erythropoietin

Esophageal varices, bleeding, and portal hypertension due to ADPKD, 4:A3, 4:A18

ESRD, *see* End-stage renal disease

Essential hypertension, *see* Hypertension

Estrogen replacement therapy for dialyzed ESRD women, 685-690

ET, biology of, *see* Endothelin biology

Ethical problems attached to donor issues, opinion polls on, 4:A4, 4:A10

Ethnicity, *see* Race and ethnicity

Etiology  
of IRD, 167-168  
*see also* specific conditions

European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry, 6:xxxii

Exit-site infections, catheter  
catheter removal and replacement for, 706-711  
exit-site povidone-iodine ointment in prevention of, 763-768

Experimental therapies of ARF, 797

Extracellular matrix (ECM)  
glomerular diseases due to fibrosis, excessive cell proliferation, and accumulation of, ETs in, 14-15  
lisinopril effects on, in membranous nephropathy, 254-264

Extremity, upper, pulse oxymetry of O<sub>2</sub> saturation in, with AV fistula before and after HD, 230-232

Faculty, future nephrology, 636-637

Familial clustering of ESRD in African Americans with SLE, 729-732

Familial idiopathic membranous nephropathy in identical twins, 115-118

Familial Mediterranean fever (fMF), light chain deposition disease complicating, 942-946

Families  
of kidney donors, patient attitudes toward offering funeral expenses to, 414  
of renal transplant candidates, effects of education program for, on living donor rates, 739-745  
*see also* Family history entries beginning with term: Family

Family history  
of heart disease, atherosclerotic vascular complications in renal transplant candidates and, 602  
of urolithiasis patients, 209

Fanconi's syndrome, nonacidotic proximal tubulopathy compared with, 493

Fe (iron)  
cytochrome P-450 as source of catalytic, in myoglobinuric ARF, 471-472  
gentamicin-induced mobilization of, from renal cortical mitochondria, 467-468  
in hypokalemic metabolic acidosis with hypermagnesuric hypermagnesemia and severe hypocalciuria, 108  
serum, screening for, prior to starting rHuEPO therapy of ESRD patients, 652  
*see also* Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy

Fe (iron) in CRF and/or ESRD patients on HD and on rHuEPO therapy, 319-333

and Fe metabolism, *see* Metabolism, Fe

Fe status evaluation in, 322

ferritin and, *see* Serum ferritin in CRF and/or ESRD

management of, *see* Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy

soluble transferrin receptor in, 325

transferrin saturation and, 323-324

zinc protoporphyrin and, 325

Felodipine for hypertension with impaired cognitive function, MRI evidence of white matter, and multi-infarct disease, 4:A2, 4:A9

Femoral vein catheters, recirculation with, 480

Ferritin, *see* Serum ferritin in CRF and/or ESRD

Fibrillary glomerulonephritis (FGN) associated with HCV infection, 132-135 with hematuria and renal insufficiency, 806-810

Fibroblasts, skin, collagen mRNA in, in IDDM nephropathy patients, 4:A4, 4:A20

Fibrosis, glomerular diseases due to ECM accumulation, excessive cell proliferation and, ETs in, 14-15

Financial incentives for kidney donation, patient attitudes toward, 410-418

Fistulas

- AV, *see* Arteriovenous fistula
- PTFE graft, effects of aspirin or ticlopidine on platelet deposition on, 560-564

FK-506 (tacrolimus), 305-307 and polyomavirus-induced interstitial nephritis in renal transplant recipients, 754-758

Fluid and electrolytes

- ET effects on tubular transport of, 8-10
- see also specific electrolytes*

FMF (familial Mediterranean fever), light chain deposition disease complicating, 942-946

Focal segmental glomerulosclerosis (FSGS) and IgAN, 528 with NS, *see* Focal segmental glomerulosclerosis with NS platelet function in, 4:A3, 4:A5 role of oncotic pressure in, 147-152 SDS-PAGE characterization of proteinuria in, 27-35 unilateral, RAS and, 936-941

Focal segmental glomerulosclerosis (FSGS) with NS in cholesterol atheroembolism, 334-344 relapsing NS, minimal change NS, C1q nephropathy and, 966-970

Folate, screening for, prior to starting rHuEPO therapy of ESRD patients, 652

Food preferences of ESRD patients on CAPD and after renal transplantation, 694

Fosinopril, chronic therapy with, in older hypertensive patients with chronic renal insufficiency, racial differences in renal response to, 897-906

Fractional area of interstitium (IFA) in arteriolar sclerosis, 912-918

Fractional distal (and proximal) solute reabsorption in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114

Free radicals

- anti-O<sub>2</sub> tea polyphenol, for CRF, 4:A3, 4:A7
- see also* Oxidants in toxic ARF

FSGS, *see* Focal segmental glomerulosclerosis

Funeral expenses, patient attitudes toward offering, to families of kidney donors, 414

Fungal disease, systemic entomophthoromycosis as, severe hypertension secondary to, 620-623

Fusion proteins, costimulatory signals and, in immunosuppression, 311

Gamma (γ)-glutamyl transpeptidase (GGT) in HCV-positive ESRD patients, 610, 611

Gastric juice NH<sub>3</sub> (ammonia) following *H pylori* eradication in ESRD patients on dialysis, 87-88

Gastrin, serum, following *H pylori* eradication in ESRD patients on dialysis, 87-88

Gender, *see* Sex

General biology of ETs, 2-3

General health care for ESRD women on dialysis, 688

General population

- Ca metabolism in, 641-642
- quality of life of, compared with quality of life of ESRD patients 3 months after start of chronic HD and/or PD, 587-588

Genetics, *see* Inheritance

Genotype

- ACE, IgAN prognosis and, 819
- lack of relationship between enzymic phenotype, severity of PH1 and, 36-44

Gentamicin nephrotoxicity, oxidant role in, 466-468

Geographic distribution of renal physicians, 783-784

GF, *see* Growth factor

GFR, *see* Glomerular filtration rate

GGS (global glomerulosclerosis)/chronic vascular disease in FSGS with NS, 339

GGT (gamma-glutamyl transpeptidase) in HCV-positive ESRD patients, 610, 611

Global glomerulosclerosis (GGS)/chronic vascular disease in FSGS with NS, 339

Glomerular diseases, *see* Glomerulopathy

Glomerular epithelial cells, ETs in, 7

Glomerular filtration rate (GFR)

- in arteriolar sclerosis, 914
- critical renal perfusion pressure and, in IRD, 169
- in elderly hypertensive patients with chronic renal insufficiency, effects of chronic ACE inhibition on, 897-906
- in long-term renal transplant recipients, 747, 749

*see also* Glomerular filtration rate, ET-1 and; Glomerular filtration rate in CRF and/or ESRD; Glomerular filtration rate in HTN; Hyperfiltration; Mesangial cell(s); GFR regulation by

Glomerular filtration rate (GFR), ET-1 and, 4

- in ischemic renal failure, 12
- in toxin-related renal injury, 14

Glomerular filtration rate (GFR) in CRF and/or ESRD, 505

MDRD study and, 888-896

- residual, 3 months after start of chronic HD and/or PD, 586, 589
- in secondary HPT with CRF, 499

Glomerular filtration rate (GFR) in HTN

- effects of antihypertensive therapy on, race and, 720-728
- endogenous EPO and, 377

Glomerular hypertension (HTN) in FSGS, 147-152

Glomerulointerstitial interaction of adhesion molecules in IgAN and MPGN, 843-850

Glomerulonephritis (GN)

crescentic, *see* Crescentic glomerulonephritis  
 CRF and, *see* Glomerulonephritis, CRF and/or ESRD and fibrillary, hematuria in, 806-810  
 with HCV infection, *see* Glomerulonephritis with HCV infection  
 ketoconazole and low-dose prednisone effects on progression of, 503-513  
 membranoproliferative, *see* Membranoproliferative glomerulonephritis  
 membranous, *see* Membranous glomerulonephritis  
 necrotizing, *see* Necrotizing glomerulonephritis  
 postinfectious, during pregnancy, ARF due to, 273-279  
 primary, steroid effects on lymphocytes in, 4:A3, 4:A17  
 proteinuria in, characterized with SDS-PAGE, 27-35  
 in transplant recipients, 420  
*see also specific conditions*  
 Glomerulonephritis (GN), CRF and/or ESRD and, 412, 414  
 albumin concentrations and, 660  
 early death prediction and, 216  
 with HPT, 863  
 in in-center HD patients, 854, 856  
 in inner-city renal transplant residents, 883  
 quality of life and, 586, 588  
 Glomerulonephritis (GN) with HCV infection, 610, 611  
 fibrillary, 132-135  
 immune complex, with HIV and HCV infections, 514-525  
 Glomerulopathy  
 CRF and, 505, 507, 891  
 with excessive cell proliferation, ECM accumulation, and fibrosis, ETs in, 14-15  
 HIV-associated, *see* Glomerulopathy, HIV-associated  
*see also specific glomerular diseases*  
 Glomerulopathy, HIV-associated  
 collapsing glomerulopathy with IC deposits and HIV and HCV infections, 519-520  
 prednisone for, 4:A3, 4:A12  
 Glomerulosclerosis (GS)  
 global, with chronic vascular disease in FSGS with NS, 339  
*see also* Focal segmental glomerulosclerosis  
 Glomerulus  
 ETs in, 6-7  
*see also* entries beginning with term: Glomerular and element: Glomerulo-  
 Glucose  
 in ESRD before and after CAPD and after renal transplantation, 695, 696  
 following parathyroidectomy for secondary HPT in HD patients, 760  
 hyperglycemia with hypernatremia in non-diabetic patients, 4:A4, 4:A14  
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 mesangial cell, in diabetic nephropathy, 153-163  
 postural hemodilution in nephrotic edema and, 628  
 Glucose polymer-containing peritoneal dialysis fluids (PDFs), effects of, on phagocytic activity, 246-253  
 Glutamate pyruvate transaminase, serum, *see* Alanine transaminase  
 Glutamic acid, in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 Glutamic-oxaloacetic transaminase, *see* Aspartate transaminase  
 Glutamine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 $\gamma$  (gamma)-Glutamyl transpeptidase in HCV-positive ESRD patients, 610, 611  
 Glutathione (GSH), role of, in glycerol-induced ARF, 472-473  
 Glyburide, oral, in NIDDM patients with and without ESRD, pharmacokinetics of, 907-911  
 Glycerol, toxic ARF due to, 468-474  
 Glycine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 Glycosuria in nonacidotic proximal tubulopathy with hypercalciuria, 493  
 Glycosylated Hb (hemoglobin) in NIDDM, 908  
 GN, *see* Glomerulonephritis  
 Gonadal hormones, sex and effects of, on progression of ADPKD, 265-272  
 Grading, *see* Histologic grading of IgAN  
 Granulocytes, serum factors inhibiting adherence of monocytes and, to saphenous vein endothelial cells during HD, 78-85  
 Gross hematuria in IgAN, 833  
 Growth, tubular, in chronic metabolic acidosis, 296-297  
 Growth factor (GF)  
 elevated hepatocyte, in children with biliary atresia, 188-192  
 platelet-derived growth factor A and B and Lp effects on mesangial cell proliferation, 922-924  
*see also* Transforming growth factor- $\beta$   
 GS, *see* Glomerulosclerosis  
 GSH (glutathione), role of, in glycerol-induced ARF, 472-473  
 Guidewire catheter replacement, silicon dual-lumen catheters for long-term HD vascular access with, 553-559  
 Gynecologic issues in dialyzed patients, 685-690  
 $H^+$  (hydrogen), tubular secretion of, in chronic metabolic acidosis, 294  
*H pylori* (*Helicobacter pylori*), eradication of, with amoxicillin and proton-pump inhibitor in dialysis patients with ESRD, 86-90  
 Hand, painful, pulse oxymetry of  $O_2$  saturation in upper extremity with AV fistula before and after HD, 230-232  
 Hb (hemoglobin)  
 glycosylated, in NIDDM, 908  
 in predialysis patients, rHuEPO and, 543  
*see also* Hb in CRF and/or ESRD patients on CAPD and/or HD  
 Hb (hemoglobin) in CRF and/or ESRD patients on CAPD and/or HD  
 and Ab response to HBV vaccine, 240  
 before and after CAPD and after renal transplantation, 695  
 in chronic HD patients, nandrolone decanoate effects on, 571  
 effects of multidisciplinary predialysis interventions on, 536  
 rHuEPO resistance and, 567  
 3 months after start of chronic HD and/or PD, 586, 589  
 HBV (hepatitis B virus) vaccine, factors influencing Ab response to, in HD patients, 239-245

HCMA, *see* Hyperchloremic metabolic acidosis

$\text{HCO}_3$  (bicarbonate)

- in ESRD, *see*  $\text{HCO}_3$  in ESRD
- in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- postural hemodilution in nephrotic edema and, 628
- in tubular acidosis, 137-138, 141, 144

$\text{HCO}_3$  (bicarbonate) in ESRD

- before and after CAPD and after renal transplantation, 695, 696
- with HPT, 863, 864

Hct, *see* Hematocrit

HCV, *see* Hepatitis C virus infection

HD, *see* Hemodialysis

HDL-C, *see* High-density lipoprotein-cholesterol

Health insurance coverage, and unemployment among inner-city renal transplant recipients, 881-887

Heart disease, family history of, and atherosclerotic vascular complications in renal transplant candidates, 602

Heart rate (HR), and rHuEPO in predialysis CRF patients, 543

*Helicobacter pylori* (*H pylori*), eradication of, with amoxicillin and proton-pump inhibitor in dialysis patients with ESRD, 86-90

Hematocrit (Hct)

- in ARF due to postinfectious nephritis in pregnancy, 274
- see also* Hematocrit in CRF and/or ESRD

Hematocrit (Hct) in CRF and/or ESRD

- with HIVAN, 551
- nifedipine effects on, 234
- parenteral Fe effects on, 328
- and rHuEPO in predialysis patients, 543

Hematuria

- in ICGN with HIV and HCV infections, 516
- in IgAN, 527, 528, 833
- nephrotic syndrome with renal insufficiency and, renal biopsy of, 806-810

Heme-oxygenase in glycerol-induced ARF, 473-474

Hemodialysis (HD)

- chronic, *see* Chronic hemodialysis
- compartmental volume loss during, 4:A1, 4:A11
- for CRF and/or ESRD, *see* Hemodialysis for CRF and/or ESRD
- home, for patients trained in self-care CAPD, 4:A1, 4:A10
- for HPT, *see* Hemodialysis for HPT
- intermittent, for ARF, 796
- mortality of patients on, 4:A1, 4:A8
- Na ramping in, beneficial and adverse effects of, 669-677
- pulse oxymetry of  $\text{O}_2$  saturation in upper extremity with AV fistula before and after, 230-232
- RenaGel effects on serum P and PTH in patients on, 4:A1, 4:A6
- serum factors inhibiting adherence of monocytes and granulocytes to HSVECs during, 78-85
- vascular access for, *see* Vascular access for HD

Hemodialysis (HD) for CRF and/or ESRD

- ABPM in patients on, 593-600
- albumin in, *see* Albumin in CRF and/or ESRD patients on CAPD and/or HD
- B cells in response to HBV vaccine in patients on, 241
- Ca and phosphate metabolism with, *see* Ca and phosphate metabolism management in CRF and/or ESRD

chronic, *see* Chronic hemodialysis

dialysate Na effects on hypertension in, 383-391

dyslipidemia and, 54-65

early mortality in patients starting HD, 214-222

factors influencing Ab response to HBV vaccine in patients on, 239-245

HPT and, *see* Hemodialysis for HPT; Hemodialysis for secondary HPT

in-center, improvement of adequacy of (1993-1995), 851-861

risk of hospitalization and, 4:A1, 4:A7-4:A8

sertraline hydrochloride effects on hypotension due to, 4:A1, 4:A8

and severe hypocalcemia and hypophosphatemia following parathyroidectomy, 759-762

SLE development 14 years after commencing, 631-632

*see also* Dialysis for CRF and/or ESRD; Patient survival on HD; Recombinant human erythropoietin for CRF and/or ESRD patients on CAPD and/or HD

Hemodialysis (HD) for HPT, 862-865

hyperphosphatemia and, 66-71

*see also* Hemodialysis for secondary HPT; Hypophosphatemia, HPT and, HD for

Hemodialysis (HD) for secondary HPT

- for advanced secondary HPT, calcitriol effects on, 4:A1, 4:A6-4:A7
- and biochemistry following parathyroidectomy, 759-762

Hemodilution, postural, in nephrotic edema, as cause of hemorrhage following renal biopsy, 627-630

Hemodynamics, *see* Blood pressure; Heart rate; Renal hemodynamics and entries beginning with terms: Blood flow

Hemoglobin, *see* Hb

Hemoglobinopathy J-Meinung, heterozygous, resistance to rHuEPO in ESRD with, 769-772

Hemolytic uremic syndrome (HUS)

- ARF with, pleural effusion complicating PD of, 4:A1, 4:A6
- endotheliopathy as continuum of, due to MMC therapy, 280-284

Hemorrhage following renal biopsy, postural hemodilution in nephrotic edema as cause of, 627-630

Henoch-Schönlein purpura (HSP)

- with IgAN and IgA abnormalities in WAS carrier, 285-287
- recurrence of, with IgA ANCA, 125-131

Heparin-induced thrombocytopenia and thrombosis, pseudo-pulmonary embolism and, 449-452

Hepatitis B virus (HBV) vaccine, factors influencing Ab response to, in HD patients, 239-245

Hepatitis C virus (HCV) infection

- ESRD patients with, renal transplantation effects on survival of, 608-614
- as factor influencing Ab response to HBV vaccine in HD patients, 239-245
- see also* Glomerulonephritis with HCV infection

Hepatocyte growth factor (HGF), elevated, in children with biliary atresia, 188-192

Heterozygous hemoglobinopathy J-Meinung, resistance to rHuEPO in ESRD with, 769-772

Heymann nephritis, passive, renoprotective properties of lisinopril in, 254-264

HGF (hepatocyte growth factor), elevated, in children with biliary atresia, 188-192

HHD (home hemodialysis) in trained self-care CAPD patients, 4:A1, 4:A10

High-bone turnover, HPT and, in normocalcemic long-term renal transplant recipients, 746-753

High-density lipoprotein-cholesterol (HDL-C) in CRF, 57, 60  
in diabetic renal transplant candidates, 602

High-school students, BP and urine analysis of, 4:A2, 4:A15

Histidine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Histologic grading of IgAN  
of biopsy specimens, 821-822  
new systems of, 953-958

Histology and histopathology  
of arteriolar sclerosis, 914  
of FSGS with NS in CAE, 338-340  
of IgAN, *see* Histology and histopathology, IgAN  
of IRD, 169-170  
of passive Heymann nephritis, 258-259  
*see also* Renal biopsy

Histology and histopathology, IgAN, 527, 530  
histologic subclassification, 829-842  
*see also* Histologic grading of IgAN

History  
of renal work notion and nonpharmacological therapies, 777-780  
*see also* Family history; Natural history

HIV infection, *see* Human immunodeficiency virus infection

HIVAN, *see* Human immunodeficiency virus-associated nephropathy

HLAs (human leukocyte antigens)  
and Ab response to HBV vaccine in HD patients, 241  
in familial idiopathic membranous nephropathy, 115-118  
peptides derived from, as immunosuppressants, 311-312

$H_2O_2$  (hydrogen peroxide), gentamicin-enhanced generation of, toxic ARF and, 466-467

Home hemodialysis (HHD) in trained self-care CAPD patients, 4:A1, 4:A10

Homeostatic response to chronic metabolic acidosis, 294-300

Hospitalization  
risk of, for HD patients, 4:A1, 4:A7-A8  
*see also* Hospitalized patients

Hospitalized patients  
early detection and management of hypertensive and diabetic renal disease in, 368-375  
for ESRD, suboptimal dialysis delivery in, 4:A2, 4:A14-A15

HPT, *see* Hyperparathyroidism

HR (heart rate), and rHuEPO in predialysis CRF patients, 543

HSP, *see* Henoch-Schönlein purpura

HSVECs (human saphenous vein endothelial cells), serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85

HTN, *see* Hypertension

Human immunodeficiency virus-associated nephropathy (HIVAN)  
HD for ESRD with, 549-552  
ICGN and, 514-525

response of, to long-term corticosteroid therapy, 624-626

Human immunodeficiency virus (HIV) infection  
ESRD and, 653  
HD for ESRD with, 549-552  
ICGN with HCV and, 514-525  
*see also* Glomerulopathy, HIV-associated

Human leukocyte antigens, *see* HLAs

Human saphenous vein endothelial cells (HSVECs), serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85

Hungry bone syndrome (severe hypocalcemia with hypophosphatemia) following parathyroidectomy for secondary HPT in ESRD patients on HD, 759-762

HUS, *see* Hemolytic uremic syndrome

Hyalinosis, arteriolar, in proteinuric GN, 30, 31

Hydrogen ( $H^+$ ), tubular secretion of, in chronic metabolic acidosis, 294

Hydrogen peroxide ( $H_2O_2$ ), gentamicin-enhanced generation of, toxic ARF and, 466-467

25-Hydroxycholecalciferol [25(OH)D], serum, in long-term renal transplant recipients, 747, 749

Hypercalcemia, HPT with hypophosphatemia and, HD with conventional Ca-containing solution enriched with P for, 288-290

Hypercalciuria in nonacidotic proximal tubulopathy, 490-495

Hyperchloremic metabolic acidosis (HCMA), 141-144  
case studies of, 143-144  
clinical approach to, 141-143

Hypercholesterolemia, myocardial infarction, renal artery stenosis and, 734

Hyperfiltration in FSGS, 147-152

Hyperglycemia with hypernatremia in non-diabetic patients, 4:A4, 4:A14

Hyperinflammatory response, PS deficiency and, 931-935

Hyperkalemia  
following parathyroidectomy for secondary HPT in HD patients, 762  
trimethoprim-sulfamethoxazole and, 959-965

Hypermagnesemia, hypomagnesuric, hypokalemic metabolic alkalosis with severe hypocalciuria and, 106-114

Hypernatremia, hyperglycemia with, in non-diabetic patients, 4:A4, 4:A14

Hyperoxaluria, *see* Primary hyperoxaluria; Primary hyperoxaluria type I

Hyperparathyroid bone disease, calcitriol therapy of, 646-647

Hyperparathyroidism (HPT)  
calciphylaxis and, 773-776  
HD for, *see* Hemodialysis for HPT  
high-bone turnover and, in normocalcemic long-term renal transplant recipients, 746-753  
with hypophosphatemia, *see* Hypophosphatemia, HPT and, HD for

Hyperphosphatemia  
and calciphylaxis in Crohn's disease without ESRD, 773-776  
RenaGel as noncalcemic phosphate binder for, in CRF, 66-71  
severe, following phosphate administration for bowel preparation in renal failure patients, 103-105

Hyperphosphaturia, isolated, severe hypophosphatemia and, with multiple myeloma, 445-448

Hypertension (HTN), 368-391  
 correlation between endogenous EPO and, 376-382  
 dialysate Na<sup>+</sup> effects on, 383-391  
 early detection and management of renal disease with, in hospitalized patients, 368-375  
 and ESRD, *see* Hypertension, CRF and/or ESRD and ET-1 in, 15-17  
 GFR in, *see* Glomerular filtration rate in HTN  
 glomerular, in FSGS, 147-152  
 in ICGN with HIV and HCV infections, 516  
 IgAN and, 833  
 myocardial infarction, renal artery stenosis and, 734  
 portal, bleeding esophageal varices and, due to ADPKD, 4:A3, 4:A18  
 race and, *see* Hypertension, race and  
 in renal transplant recipients, 420, 883  
 as risk factor for presence of atherosclerotic RAS in IRD, 173  
 severe, secondary to systemic entomophthoromycosis, 620-623  
 therapy of, *see* Antihypertensive therapy  
*see also* specific conditions

Hypertension (HTN), CRF and/or ESRD and, 412, 414, 679  
 albumin concentrations and, 660  
 in chronic HD patients, 581  
 early death prediction and, 216  
 with HCV infection, 610, 611  
 with HPT, 863  
 in in-center HD patients, 854, 856  
 rHuEPO therapy and, 653

Hypertension (HTN), race and  
 and antihypertensive drug effects on GFR, 720-728  
 and familial clustering of ESRD with SLE, 731  
 racial differences in renal response to chronic fosinopril and/or lisinopril therapy in older hypertensive patients with chronic renal insufficiency, 897-906  
 relationship between renal allograft survival and, 419-427

SLC associated with insulin resistance, albuminuria and, 45-53

Hypertensive nephrosclerosis, race and, 720-728  
 Hypertrophic effects of AI and glucose in diabetic nephropathy, 153-163

Hypertrophy, left ventricular, and rHuEPO for predialysis CRF patients, 541-548

Hypoalbuminemia  
 in children with biliary atresia, 189  
 in CRF and/or ESRD patients on HD, 658-668

Hypocalcemia  
 hyperphosphatemia and, following phosphate administration for bowel preparation in renal failure patients, 103-105  
 severe, following parathyroidectomy for secondary HPT in HD patients, 759-762

Hypocalciuria, severe, hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and, 106-114

Hypocomplementemia in ICGN patients with HIV and HCV infections, 516

Hypogonadism, rHuEPO effects on, 4:A2, 4:A11-A12

Hypokalemia  
 in children with biliary atresia, 189  
 in nonacidotic proximal tubulopathy with hypercalcuria, 493

Hypokalemic metabolic alkalosis with hypomagnesuric hypomagnesemia and severe hypocalciuria, 106-114

Hypomagnesuric hypermagnesemia, hypokalemic metabolic alkalosis with severe hypocalciuria and, 106-114

Hypophosphatemia  
 in nonacidotic proximal tubulopathy, 490-495  
*see also* Ca, hypophosphatemia and; Hypophosphatemia, HPT and, HD for; Severe hypophosphatemia

Hypophosphatemia, HPT and, HD for  
 following parathyroidectomy for secondary HPT in HD patients, 759-762  
 with hypercalcemia, HD with conventional Ca-containing solution enriched with P for, 288-290

Hypotension, HD, sertraline hydrochloride effect on, 4:A1, 4:A8

Hypouricemia in children with biliary atresia, 189

IC(s) (immune complexes), collapsing glomerulopathy with deposits of, HIV and HCV infections and, 519-520

ICAM1 (immune complex adhesion molecule 1)/LFA1 and ICAM3 (immune complex adhesion molecule 3)/LFA1 interactions in IgAN and MPGN, 843-850

ICGN (immune complex glomerulonephritis) with HIV and HCV infection, 514-525

IDDM (insulin-dependent diabetes mellitus), *see* Diabetes mellitus

Identical twins, idiopathic membranous nephropathy in, 115-118

Idiopathic membranous nephropathy (IMN)  
 in the elderly, therapy of, 200-206  
 in identical twins, 115-118

IDLs (intermediate-density lipoproteins), effects of, on mesangial cell proliferation, 919-930

IFA (fractional area of interstitium) in arteriolar sclerosis, 912-918

IgA (immunoglobulin A)  
 in ascitic patients, 395  
 IgA with abnormalities of, and HSP in WAS carrier, 285-287

IgA (immunoglobulin A) antineutrophil cytoplasmic antibodies (ANCA), IgAN recurrence with, 125-131

IgA nephropathy (IgAN; Berger's disease)  
 glomerulointerstitial interaction of adhesion molecules in, 843-850  
 hemorheological alterations in, 4:A3, 4:A14  
 histologic grading of, *see* Histologic grading of IgAN  
 HSP with IgA abnormalities and, in WAS carrier, 285-287  
 natural history and risk factors for, 526-532  
 progression of, to ESRD, *see* Progression of (and to) CRF and/or ESRD, IgAN  
 recurrence of, with IgA ANCA following renal transplantation, 125-131  
*see also* Renal biopsy in IgAN

IgAN, *see* IgA nephropathy

IgG (immunoglobulin G) in ascitic patients, 395

IgM (immunoglobulin M) in ascitic patients, 395

IHD (intermittent hemodialysis) for ARF, 796

IL-, *see entries beginning with term:* Interleukin-IMCD (inner medullary collecting duct), fluid and electrolyte transport by, ET effects on, 8-10

Immune cells, interstitial expression of ICAM1 and ICAM3 and interstitial infiltration of, 844-845

Immune complex(es) (ICs), collapsing glomerulopathy with deposits of, HIV and HCV infections and, 519-520

Immune complex adhesion molecule 1 (ICAM1)/LFA1 and immune complex adhesion molecule 3 (ICAM3)/LFA1 interactions in IgAN and MPGN, 843-850

Immune complex glomerulonephritis (ICGN) with HIV and HCV infection, 514-525

Immunogenetic markers of IgAN prognosis, 818-819

Immunoglobulin, *see entries beginning with acronym: Ig*

Immunosuppression, *see Clinical studies and trials of new immunosuppressive agent(s) and specific immunosuppressive agents*

IMN, *see Idiopathic membranous nephropathy*

In-center hemodialysis (HD) for CRF and/or ESRD, improvement in delivery of (1993-1995), 851-861

Income level

- and attitudes toward financial incentives for kidney donation, 412, 414
- of inner-city renal transplant residents, unemployment and, 883-885

Indications

- for dialysis in ARF, 796
- for renal biopsy in IgAN, 527
- for tunneled permanent venous catheters, 4:A2, 4:A16
- see also specific conditions*

Infarction

- felodipine for hypertension with impaired cognitive function, MRI evidence of white matter, and multi-infarct disease, 4:A2, 4:A9
- myocardial, *see Myocardial infarction*

Infections

- ARF due to GN following, during pregnancy, 273-279
- opportunistic, in renal transplantation, 754-758
- PD-related, *see Infections, PD-related*
- silicon dual-lumen catheter-related, 556-557
- see also specific infections*

Infections, PD-related

- povidone-iodine ointment in prevention of, 763-768
- see also Exit-site infections, catheter; Peritonitis on CAPD; Tunnel infections*

Inflammation

- and albumin concentrations in ESRD patients on HD, 658-668
- hyperinflammatory response and PS deficiency, 931-935

Inheritance

- vertical PH1, 36-44
- see also Alleles; Families; Genotype; mRNA; Phenotype entries beginning with terms: Autosomal dominant, Heterozygous and specific inherited conditions*

Injury, *see Myocardial injury; Renal injury*

Inner-city renal transplant recipients, unemployment among, 881-887

Inner medullary collecting duct (IMCD), fluid and electrolyte transport by, ET effects on, 8-10

Insulin

- in ESRD before and after CAPD and after renal transplantation, 695, 696
- see also Insulin resistance*

Insulin-dependent diabetes mellitus, *see Diabetes mellitus*

Insulin resistance, 45-65

- role of abdominal adiposity and, in dyslipidemia of CRF, 54-65

SLC associated with albuminuria and, race and, 45-53

Integrin, and monocyte and granulocyte adherence to HSVECs during HD, 78-85

$\alpha$  (alpha)-Interferon for fibrillary GN associated with HCV infection, 132-135

Interleukin-1 $\beta$  (IL-1 $\beta$ ), and Lp effects on mesangial cell proliferation, 926-927

Interleukin-4 (IL-4), effects of, on neutrophil infiltration in nephritis, 4:A3, 4:A16-A17

Interleukin-6 (IL-6), and Lp effects on mesangial cell proliferation, 921-922

Interleukin-8 (IL-8), expression of, following renal transplantation, rejection and, 871-880

Intermediate-density lipoproteins (IDLs), effects of, on mesangial cell proliferation, 919-930

Intermittent hemodialysis (IHD) for ARF, 796

Interstitial nephritis

- CRF and, *see Interstitial nephritis, CRF and/or ESRD and effects of ketoconazole and low-dose prednisone on progression of, 503-513*
- polyomavirus-induced, in renal transplant recipients, 754-758

Interstitial nephritis, CRF and/or ESRD and chronic, 653

- in chronic HD patients, residual renal function preservation with PS dialyzers and, 581
- quality of life and, 586, 588

Interstitial

- fractional area of, in arteriolar sclerosis, 912-918
- immune cell infiltration into, ICAM1 and ICAM3 expression and, 844-845
- see also entries beginning with terms: Glomerulointerstitial, Interstitial*

Intestinal Ca (calcium), calcitriol effects on absorption of, 642

Intestinal flora, and Cr degradation in CRF, 72-77

Intradialytic parenteral nutrition, effects of, on Kt/V, 4:A2, 4:A12-A13

Intradialytic symptoms, Na ramping and, 671-672

Ionic mechanisms, 974-976

- of mesangial cell contraction, 974-975
- of mesangial cell relaxation, 975-976

IRD, *see Ischemic renal disease*

Iron, *see Fe*

Iron saccharate in CRF patients on HD, rHuEPO resistance and, 567

Ischemic renal disease (IRD), 167-187

- anatomic correlates of, 168-169
- causes of, 167-168
- clinical presentation of, 175-176
- defined, 167
- diagnosis of, 176-178
- natural history of, 173-174
- pathophysiology of, 169-171
- prevalence of, 175
- prevalence of atherosclerotic RAS in, 171-173
- renal artery stenosis and, 733-738
- survival with, 182-183
- therapy of, 179-182

Ischemic renal failure

- ETs in, 12

*see also* Ischemic renal disease  
 Isoflurane, effects of, on proximal tubular cell energetics, 4:A1, 4:A12  
 Isolated hyperphosphaturia, severe hypophosphatemia and, with multiple myeloma, 445-448  
 Isolated proximal renal tubular acidosis (pRTA), 143  
 Isoleucine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 Japanese subjects, natural history and risk factors for IgAN in, 526-532  
 K (potassium)  
   ACE inhibitor effects on, 4:A2, 4:A20-A21  
   effects of depletion of, on cortical and medullary membrane protein and lipids, 4:A4, 4:A8-A9  
   following parathyroidectomy for secondary HPT in HD patients, 760  
   in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
   plasma, in ascitic patients, 394  
   postural hemodilution in nephrotic edema and, 628  
   serum, *see* Serum K  
   *see also* Hyperkalemia; Hypokalemia; Hypokalemic metabolic alkalosis  
 Ketoconazole, effects of low-dose prednisone and, on progression of CRF, 503-513  
 Kidneys  
   donation of, *see* Donors  
   weight of, in ADPKD, 267-268  
   *see also* entries beginning with term: Renal and element; Neph-,  
 Kinase, CK-MB and myocardial injury diagnosis in chronic HD patients, 399-403  
 Kt/V  
   and Ab response to HBV vaccine, 240  
   intradialytic parenteral nutrition effects on, 4:A2, 4:A12-A13  
   nifedipine effects on, 234  
   in peripheral AV versus CVV access, 487-488  
   3 months after start of chronic HD and/or PD, 586, 589  
   *see also* Dialysis delivery; Urea reduction ratio  
 Lactate, levels of, in glucose polymer-containing PDFs, 247  
 Lactate dehydrogenase (LDH) in ARF due to postinfectious GN during pregnancy, 274  
 LD(s) (living donors), increase in, with formal education program for families of renal transplantation candidates, 739-745  
 LDL(s), *see* Low-density lipoprotein(s)  
 LDL-C, *see* Low-density lipoprotein-cholesterol  
 Lectin, binding of, to IgA in IgAN with HSP in WAS carrier, 286  
 Leflunomide, 308  
 Left ventricular hypertrophy (LVH), and rHuEPO for predialysis CRF patients, 541-548  
 Leucine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 Leukocytes, *see* White blood cell count and specific leukocytes  
 LFA1, ICAM1 and ICAM3 interactions with, in IgAN and MPGN, 843-850  
 Li, *see* Lithium  
 Light chain deposition disease complicating fMF, 942-946  
 Line reversal, recirculation and, in peripheral AV versus CVV access, 482-483  
 Lipids  
   cortical and medullary membrane, effects of K depletion on, 4:A4, 4:A8-A9  
   level of, in diabetic renal transplant candidates, 602  
   postural hemodilution in nephrotic edema and, 628  
   role of insulin resistance and abdominal adiposity in dyslipidemia of CRF, 54-65  
   serum, androgen effects on levels of, in chronic HD patients, 569-575  
   *see also* specific lipids  
 Lipoprotein (Lp)  
   effects of, on mesangial cell proliferation, 919-930  
   nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575  
   *see also* Intermediate-density lipoproteins; Lipoprotein(a); Low-density lipoprotein(s)  
 Lipoprotein(a) [Lp(a)]  
   in CRF, 57  
   as CV risk factor in dialyzed ESRD patients, 4:A2, 4:A13  
   serum, nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575  
 Lisinopril  
   chronic therapy with, in older hypertensive patients with chronic renal insufficiency, racial differences in renal response to, 897-906  
   renoprotective properties of, in membranous nephropathy, 254-264  
 Lithiasis, *see* Nephrolithiasis; Urolithiasis  
 Lithium (Li)  
   ESRD following therapy with, 4:A3, 4:A7  
   insulin resistance and albuminuria associated with sodium-lithium countertransport, race and, 45-53  
   tubular cysts, adenoma, and adenocarcinoma due to, 4:A3, 4:A5  
 Livedo reticularis, primary hyperoxaluria with renal failure, retinopathy, and peripheral neuropathy, 947-952  
 Liver disease, autosomal dominant polycystic, portal hypertension and bleeding esophageal varices due to, 4:A3, 4:A18  
 Living donors (LDs), increase in, with formal education program for families of renal transplantation candidates, 739-745  
 LMW (low molecular weight; tubular) proteins in GN with proteinuria, clinical significance and prognostic value of, 27-35  
 Long-term corticosteroid therapy of HIVAN, response to, 624-626  
 Long-term renal transplant recipients, normocalcemic, high-bone turnover and HPT in, 746-753  
 Long-term vascular access for HD, catheters for  
   silicon dual-lumen catheters with guidewire replacement of catheters, 553-559  
   tunneled permanent venous catheters for, 4:A2, 4:A16  
 Low-density lipoprotein(s) (LDLs)  
   in CRF, 60  
   effects of, on mesangial cell proliferation, 919-930  
   *see also* Low-density lipoprotein-cholesterol

Low-density lipoprotein-cholesterol (LDL-C)  
in CRF, 57  
in diabetic renal transplant candidates, 602

Low-dose prednisone, effects of ketoconazole and, on progression of CRF, 503-513

Low molecular weight (tubular; LMW) proteins in GN with proteinuria, clinical significance and prognostic value of, 27-35

Low-turnover bone disease, calcitonin effects in dialysis patients with, 4:A2, 4:A19

Lp, *see* Lipoprotein

Lupus nephritis  
diffuse proliferative, PS deficiency and, 931-935  
HCV infection and, 610  
membranous, with P-ANCA-associated pauci-immune segmental necrotizing GN, 119-124  
meta-analysis of treatment of, 193-199  
*see also* Systemic lupus erythematosus

LVH (left ventricular hypertrophy), and rHuEPO for predialysis CRF patients, 541-548

Lymphocytes  
corticosteroid effects on, in primary GN, 4:A3, 4:A17  
in HD patients, *see* Lymphocytes in HD patients

Lymphocytes in HD patients  
effects of nifedipine discontinuation on cytosolic Ca and B cell proliferation with CRF, 233-238  
phenotyping of, effects of rHuEPO on phagocyte activity and, 866-870  
in response to HBV vaccine, 241

Lysine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Macrophage population, cancer antigen 125 and dialysate, in stable CAPD patients, peritoneal transport parameters and, 699-705

Magnesium, *see* Mg

Magnetic resonance imaging (MRI), felodipine for hypertension with impaired cognitive function, multi-infarct disease, and evidence of white matter as seen with, 4:A2, 4:A9

Malignant disease, *see* Multiple myeloma; Renal transplantation in patients with malignant disease

MAP (mean arterial pressure), *see* Blood pressure

Marital status  
and quality of life 3 months after start of chronic HD and/or PD, 586  
vasectomy as risk factor for urolithiasis and, 209

MC(s), *see* Mesangial cell(s)

MCNS, *see* Minimal change nephrotic syndrome

MDRD (Modification of Diet in Renal Disease) study of quality of life with CRF, 888-896

Mean arterial pressure, *see* Blood pressure

Medical management  
of IRD, 182  
*see also* Therapy and management and specific drugs and specific conditions

Medical practice, general, future of, 638-639

Medullary collecting duct, inner, fluid and electrolyte transport by, ET effects on, 8-10

Medullary membranes, effects of K depletion on lipids and protein of, 4:A4, 4:A8-A9

Membranoproliferative glomerulonephritis (MPGN)  
glomerulointerstitial interaction of adhesion molecules in, 843-850  
with HIV and HCV infections, 517-518

SDS-PAGE characterization of proteinuria in, 27-35

Membranous glomerulonephritis (GN)  
IgAN and, 528  
SDS-PAGE characterization of proteinuria in, 27-35  
SLE and uterine vasculitis with, 277-279

Membranous lupus nephritis with P-ANCA-associated pauci-immune segmental necrotizing GN, 119-124

Membranous nephropathy (MN)  
with HIV and CV infections, 519  
idiopathic, *see* Idiopathic membranous nephropathy  
renoprotective properties of lisinopril in, 254-264

Memphis scoring system for renal biopsy findings in IgAN, 825-826

Mesangial cell(s) (MCs), 147-163  
ETs in, 6-7  
in FSGS, 147-152  
glucose in, in diabetic nephropathy, 153-163  
LP effects on proliferation of, 919-930  
*see also* Mesangial cell(s), GFR regulation by

Mesangial cell(s) (MCs), GFR regulation by, 971-981  
capillary-mesangial biomechanical unit in, 972  
effects of disease on mesangial cell tone in, 976-977  
GFR regulation by vasoactive agents and, 972-973  
mesangial cell contraction in, *see* Mesangial cell contraction in GFR regulation  
mesangial cell relaxation in, 975-976

Mesangial cell (MC) contraction in GFR regulation, 973-976  
mechanisms of, 973-975  
renal disease and impaired, 976

Mesangial proliferative glomerulonephritis (GN) with HIV and HCV infections, 518-519

Mesothelial cells  
cancer antigen 125 dialysate population of, in stable CAPD patients, peritoneal transport parameters and, 699-705  
effects of PDFs on, 404-409

Messenger ribonucleic acid, *see* mRNA

Metabolic acidosis  
influence of, on nutrition, 5:xlii-xliii  
*see also* Chronic metabolic acidosis; Hyperchloremic metabolic acidosis

Metabolic alkalosis, hypokalemic, with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114

Metabolism  
bone, with reduced renal function, 4:A3, 4:A9  
*see also* Ca and phosphate metabolism management in CRF and/or ESRD; Metabolism, Fe and entries beginning with term: Metabolic

Metabolism, Fe, 320-322  
in ESRD, 321-322  
normal, 320-321

Metalloproteinase-1 (MMP-1) mRNA (messenger ribonucleic acid) in skin fibroblasts of diabetic nephropathy patients, 4:A4, 4:A20

Methionine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

MFs (myofibroblasts), arteriolar sclerosis and, in diabetic nephropathy, 912-918

Mg (magnesium)  
 in glucose polymer-containing PDFs, 247  
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 in hypokalemic metabolic alkalosis with hypomagnesuria and hypermagnesemia and severe hypocalciuria, 108

MI, *see* Myocardial infarction

Minimal change nephrotic syndrome (MCNS)  
 FSGS, C1q nephropathy and, and relapsing NS, 966-970  
 platelet function in, 4:A3, 4:A5

Mitochondria, *see* Renal cortical mitochondria

Mitomycin C (MMC), endotheliopathy as continuum of HUS due to, 280-284

Mizoribine, 308-309

MMC (mitomycin C), endotheliopathy as continuum of HUS due to, 280-284

MMF (mycophenolate mofetil), 309-310

MMP-1 (metalloproteinase-1) mRNA (messenger ribonucleic acid) in skin fibroblasts of diabetic nephropathy patients, 4:A4, 4:A20

MN, *see* Membranous nephropathy

Modification of Diet in Renal Disease (MDRD) study of quality of life with CRF, 888-896

Monocytes  
 effects of glucose polymer-containing PDFs on activity of, 246-253  
 serum factors inhibiting adherence of granulocytes and, to HSVECs during HD, 78-85

Mortality of HD patients, 4:A1, 4:A8  
 early, of ESRD patients starting HD or PD, 214-222  
 with silicon dual-lumen HD catheters, 555  
*see also specific conditions*

MPGN, *see* Membranoproliferative glomerulonephritis

MPO (myeloperoxidase), and recurrent IgAN with IgA AN-CAs, 125-131

MRI (magnetic resonance imaging), felodipine for hypertension with impaired cognitive function, multi-infarct disease, and evidence of white matter as seen with, 4:A2, 4:A9

mRNA (messenger ribonucleic acid)  
 collagen, MMP-1, and tissue inhibitor of metalloproteinase-1, in skin fibroblasts of IDDM nephropathy patients, 4:A4, 4:A20

ECM, effects of lisinopril on expression of, in PHN, 259

Mucormycosis, pulmonary, in diabetic renal transplant recipients, 461-464

Multidisciplinary predialysis interventions, 533-540

Multi-infarct disease, felodipine for hypertension with impaired cognitive function, MRI evidence of white matter and, 4:A2, 4:A9

Multiple myeloma, isolated hyperphosphaturia with severe hypophosphatemia in, 445-448

Mycophenolate mofetil (MMF; RS-61443), 309-310

Myeloma, multiple, isolated hyperphosphaturia with severe hypophosphatemia in, 445-448

Myeloperoxidase (MPO), and recurrent IgAN with IgA AN-CAs, 125-131

Myocardial infarction (MI)  
 in diabetic renal transplant candidates, 601-607  
 prevalence and predictors of renal artery stenosis in, 733-738

Myocardial injury in chronic HD patients, CK-MB and, 399-403

Myofibroblasts (MFs), arteriolar sclerosis and, in diabetic nephropathy, 912-918

Myoglobinuric acute renal failure (ARF), cytochrome P-450 as source of catalytic Fe in, 471-472

N (nitrogen), *see* Azotemia; Urea nitrogen

Na (sodium)  
 dialysate, effects of, on hypertension, 383-391  
 in glucose polymer-containing PDFs, 247  
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 in hypokalemic metabolic alkalosis with hypomagnesuria and hypermagnesemia and severe hypocalciuria, 108  
 Na ramping in HD, 669-677  
 plasma, in ascitic patients, 408  
 postural hemodilution in nephrotic edema and, 628  
 serum, *see* Serum Na  
 urinary excretion of, *see* Urinary excretion, Na  
*see also* Hypernatremia; Natriuretic peptide; Sodium-dodecyl sulphate-polyacrylamide gel electrophoresis; Sodium-lithium countertransport

NaCl (sodium chloride), dietary, influence of, on antiproteinuric effects of Ca channel blockers, 800-805

Nandrolone decanoate, serum Lp(a) concentrations reduced by, in chronic HD patients, 569-575

Natriuretic peptide, atrial, postural hemodilution in nephrotic edema and, 628

Natural history  
 of IgAN, 526-532  
 of IRD, 173-174

Necrotizing glomerulonephritis (GN)  
 crescentic, ANCA-associated vasculitis and, 96-102  
 pauci-immune segmental, membranous lupus nephritis associated with, 119-124

Nephritis  
 IL-4 effects on neutrophil infiltration in, 4:A3, 4:A16-A17  
 passive Heymann, renoprotective properties of lisinopril in, 254-264  
*see also* Glomerulonephritis; Interstitial nephritis; Lupus nephritis; Perinephritis; Pyelonephritis

Nephrocalcinosis  
 nonacidotic proximal tubulopathy and, 493  
 PH and, *see* Nephrocalcinosis, PH and

Nephrocalcinosis, PH and  
 PH1, 36-44  
 with renal failure, 947-952

Nephrolithiasis, and nonacidotic proximal tubulopathy, 490-495

Nephrology, future aspects of, 633-639  
 future utilization of nephrology services and supply of renal physicians, 789-790; *see also* Renal physicians, supply of  
 nephrology faculty, 636-637  
 practice, 638-639  
 research, 637  
 training of nephrologists, 633-636

Nephromegaly, elevated HGF in children with biliary atresia and, 188-192

Nephrosclerosis

body weight, sex and, 4:A4, 4:A16  
 hypertensive, race and, 720-728

Nephrotic edema, postural hemodilution in, as cause of hemorrhage following renal biopsy, 627-630

Nephrotic syndrome (NS)  
 FSGS and, *see* Nephrotic syndrome, FSGS and with hematuria and renal insufficiency, renal biopsy of, 806-810  
 IgAN with, 528, 530  
 minimal change, *see* Minimal change nephrotic syndrome

Nephrotic syndrome (NS), FSGS and, 147-152  
 in cholesterol atheroembolism, 334-344

Nephrotoxicity of CsA  
 ARF due to, 474-475  
 role of ETs in, 12-13

Nephrotoxin  
 in ARF, 795-796  
*see also* Nephrotoxicity of CsA; Toxic acute renal failure

Neurohumoral substances, and rHuEPO in predialysis CRF patients, 545

Neuropathy, peripheral, primary hyperoxaluria with renal failure, livedo reticularis, and retinopathy, 947-952

Neutrophil(s)  
 effects of glucose polymer-containing PDFs on activity of, 246-253  
 in nephritis, IL-4 effects on infiltration of, 4:A3, 4:A16-A17

New immunosuppressive agent(s), *see* Clinical studies and trials of new immunosuppressive agent(s)

NH<sub>3</sub> (ammonia)  
 gastric juice, following *H pylori* eradication in ESRD patients on dialysis, 87-88  
 synthesis of, in chronic metabolic acidosis, 296

NH<sub>4</sub> (ammonium)  
 synthesis of, in chronic metabolic acidosis, 296  
 urinary excretion of, in tubular acidosis, 139-140

NIDDM (non-insulin-dependent diabetes mellitus), *see* Diabetes mellitus

Nifedipine, effects of discontinuation of, on cytosolic Ca, and B cell proliferation in CRF patients on HD, 233-238

Nitrate, excretion of, in CRF, ketoconazole plus low-dose prednisone effects on, 503-513

Nitric oxide (NO), amino acids and pathway of, in acute peritonitis on CAPD, 712-719

Nitrite in acute peritonitis on CAPD, 715-716

Nitrogen, *see* Azotemia; Urea nitrogen

NO (nitric oxide), amino acids and pathway of, in acute peritonitis on CAPD, 712-719

Nonacidototic proximal tubulopathy, autosomal dominant, 490-495

Noncalcemic phosphate binder, *see* RenaGel

Nondiabetic end-stage renal disease (ESRD) with HPT, 863-864

Nondiabetic patients, hyperglycemia with hypernatremia in, 4:A4, 4:A14

Non-insulin-dependent diabetes mellitus, *see* Diabetes mellitus

Nonpharmacological therapies, renal work notion and introduction of, 777-780

Nontransport function of renal tubules, effect of tubule-derived ETs on, 11

Normal Fe (iron) metabolism, 320-321

Normal population, *see* General population

Normalized protein catabolic rate (nPCR) 3 months after start of chronic HD and/or PD for CRF and/or ESRD, 586, 589

Normocalcemic long-term renal transplant recipients, high-bone turnover and HPT in, 746-753

nPCR (normalized protein catabolic rate) 3 months after start of chronic HD and/or PD for CRF and/or ESRD, 586, 589

NS, *see* Nephrotic syndrome

Nutrition, *see* Chronic renal failure, nutrition in; Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy *entries beginning with terms:* Dietary, Parenteral

O<sub>2</sub>, *see* entries beginning with term: Oxygen

O<sub>2</sub><sup>-</sup> (superoxide), effects of glucose polymer-containing PDFs on, 249-250

OG37-325 (cyclosporin G), 305

25(OH)D (25-hydroxycholecalciferol), serum, in long-term renal transplant recipients, 747, 749

1,25-(OH)<sub>2</sub>D<sub>3</sub>, *see* Calcitriol

Older patients, *see* Elderly, the

Once-a-day lisinopril and/or fosinopril, efficacy of, 901-902

Oncotic pressure, role of, in FSGS, 147-152

Opinion polls on ethical problems related to donor issues, 4:A4, 4:A10

Opportunistic infections in renal transplantation, 754-758

Oral Fe (iron), Fe management in ESRD patients on HD and on rHuEPO with, 325-326

Oral glyburide in NIDDM patients with and without ESRD, pharmacokinetics of, 907-911

Ornithine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Osmolarity of glucose polymer-containing PDFs, 247

Osteocalcin, serum, and high-bone turnover and HPT in normocalcemic long-term renal transplant recipients, 746-753

Osteodystrophy, renal, *see* Bone disease

Outcome  
 of ANCA-associated vasculitis following renal transplantation, 96-102  
 of ARF, *see* Acute renal failure, management and outcome of  
 of calcitriol pulses in advanced secondary HPT patients on HD, 4:A1, 4:A6-A7  
 of ESRD with HIVAN, HD and, 549-552; *see also* Mortality of HD patients  
 of exit-site povidone-iodine ointment in prevention of PD-related infections, 766  
 IgAN, *see* Outcome, IgAN  
 of IMN in the elderly, 202, 203  
 of long-term HD vascular access with tunneled permanent venous catheters, 4:A2, 4:A16  
 of multidisciplinary predialysis interventions, 533-540  
 of renal transplant recipients with thyroid cancer, 4:A4, 4:A14  
 of surgical therapy of IRD, 179-181  
 of *Xanthomonas maltophilia* peritonitis, 92  
*see also* Patient survival; Prognosis; Renal allograft survival and specific conditions

Outcome, IgAN, 529-530  
 histologic subclassification and, 831-837  
 indicators of patient survival, 840  
*see also* Prognosis, IgAN; Renal survival in IgAN

Oxidants in toxic ARF, 465-477  
 CsA and, 474-475  
 gentamicin and, 466-468  
 glycerol and, 468-474  
 Oxidized low-density lipoproteins (LDLs), effects of, on mesangial cell proliferation, 919-930

Oxygen ( $O_2$ )  
 saturation of, in upper extremity with AV fistula before and after HD, pulse oxymetry of, 230-232  
*see also* Free radicals; Oxidants in toxic ARF

Oxygenase, heme-, in glycerol-induced ARF, 473-474

Oxymetry, pulse, of  $O_2$  saturation in upper extremity with AV fistula before and after HD, 230-232

P (phosphorus)  
 in HPT, *see* P in HPT  
 in hypokalemic metabolic alkalosis with hypomagnesuria  
 hypermagnesemia and severe hypocalciuria, 108  
 serum, *see* Serum P

P (phosphorus) in HPT  
 dietary, in secondary HPT with CRF, 496-502  
 with hypercalcemia and hypophosphatemia, conventional Ca-containing dialysis solutions enriched with, 288-290

PCO<sub>2</sub> (carbon dioxide partial pressure) in alkaline urine in tubular acidosis, 138-139, 141

Paclitaxel (Taxol), effects of, on progression of PKD, 435-444

Page kidney (constrictive perinephritis), hypertension secondary to, 620-623

Painful hand, pulse oxymetry of  $O_2$  saturation in, with AV fistula before and after HD, 230-232

P-ANCA, *see* Perinuclear antineutrophil cytoplasmic antibodies

Paracentesis, described, 392

Paradoxical cerebral air embolism due to central venous catheter, 453-455

Parathormone, influence of, on ambulatory BP in CAPD patients, HD patients, and renal transplant recipients, 593-600

Parathyroid hormone (PTH)  
 plasma, in nonacidotic proximal tubulopathy with hypercalcemia, 493  
*see also* Hyperparathyroidism; Parathyroid hormone in CRF and/or ESRD patients; Serum parathyroid hormone

Parathyroid hormone (PTH) in CRF and/or ESRD patients  
 effects of multidisciplinary predialysis interventions on, 536  
 on HD, 57, 240  
 screening for intact, prior to starting rHuEPO therapy, 652

Parathyroidectomy for secondary HPT in HD patients, biochemistry following, 759-762

Parenchymal renal disease in chronic HD patients, residual renal function preservation with PS dialyzers and, 581

Parenteral Fe (iron) for ESRD patients on HD and on rHuEPO, 326-329

Parenteral nutrition  
 in ARF management, 795  
 intradialytic, effect of, on Kt/V, 4:A2, 4:A12-A13

Passive Heymann nephritis (PHN), renoprotective properties of lisinopril in, 254-264

Pathology, pathogenesis, and pathophysiology  
 of IgA nephropathy, hemorrheological alterations in, 4:A3, 4:A14  
 of IRD, 169-171  
*see also* specific conditions

Patient attitudes toward financial incentives for kidney donation, 410-418

Patient characteristics, *see* Age; Body mass index; Body weight; Educational status; Employment status; Marital status; Race and ethnicity; Sex

Patient education on multidisciplinary predialysis interventions, 533-540

Patient survival  
 with HCV-positive ESRD, effects of renal transplantation on, 608-614  
 with IgAN, indicators of, 840  
 with IRD, 182-183  
 with renal transplantation, CMV infection effects on, 428-434  
*see also* Patient survival on HD

Patient survival on HD  
 with ESRD and HIVAN, 549-552  
 or PD, prealbumin as predictor of, 4:A1, 4:A5-A6

Pauci-immune segmental necrotizing glomerulonephritis (GN), P-ANCA-associated, membranous lupus nephritis with, 119-124

PCR, *see* Protein catabolic rate on HD

PD, *see* Peritoneal dialysis

PDE (peritoneal dialysis effluent), cell population in, in stable CAPD patients, 699-705

PDFs, *see* Peritoneal dialysis fluids

PDGF (platelet-derived growth factor) A and B, and Lp effects on mesangial cell proliferation, 922-924

Pediatric conditions, *see* Children

Peptide  
 atrial natriuretic, postural hemodilution in nephrotic edema and, 628  
 HLA-derived, as immunosuppressants, 311-312  
*see also* specific peptides

Percutaneous mechanical thrombectomy, AV fistula salvage with, 4:A1, 4:A9

Percutaneous transluminal renal angioplasty (PTRA)  
 of IRD, 180-181

SCR following, in elderly patients with RAS, 4:A4, 4:A11

Perfusion pressure, critical renal, IRD and, 169

Perinephritis, constrictive, hypertension secondary to, 620-623

Perinuclear antineutrophil cytoplasmic antibodies (P-ANCA)  
 membranous lupus nephritis associated with, pauci-immune segmental necrotizing GN with, 119-124  
 vasculitis associated with, following renal transplantation, 96-102

Peripheral arteriovenous (AV) versus central venous (CVV) vascular access, 479-489

dialysis delivery with, *see* Dialysis delivery with peripheral AV versus CVV access

dialyzer blood flow and, 486-487  
recirculation in, *see* Recirculation in peripheral AV versus CVV access  
venovenous disequilibrium and regional blood flow model in, *see* Regional blood flow model in peripheral AV versus CVV access; Venovenous disequilibrium in peripheral AV versus CVV access

Peripheral neuropathy, primary hyperoxaluria with renal failure, livedo reticularis, and retinopathy, 947-952

Peripheral vein recirculation method, defined, 488

Peritoneal dialysis (PD)  
for ARF with HUS, pleural effusion complicating, 4:A1, 4:A6  
infections related to, *see* Infections, PD-related  
*see also* Continuous ambulatory peritoneal dialysis; Peritoneal dialysis for CRF and/or ESRD; Peritoneal dialysis effluent; Peritoneal dialysis fluids

Peritoneal dialysis (PD) for CRF and/or ESRD  
Ca and phosphate metabolism in, *see* Ca and phosphate metabolism management in CRF and/or ESRD  
early mortality in patients starting, 214-222  
prealbumin as predictor of survival on, 4:A1, 4:A5-A6  
quality of life 3 months after start of, 576-583  
*see also* Continuous ambulatory peritoneal dialysis for CRF and/or ESRD; Dialysis for CRF and/or ESRD

Peritoneal dialysis effluent (PDE), cell population in, in stable CAPD patients, 699-705

Peritoneal dialysis fluids (PDFs)  
effects of, on mesothelial cells, 404-409  
effects of glucose polymer-containing, on phagocytic activity, 246-253

Peritoneal transport parameters, cancer antigen 125 and dialysate cell population in stable CAPD patients and, 699-705

Peritonitis on CAPD, 706-719  
acute, NO pathway and amino acids in, 712-719  
catheter infections and, 706-711  
effects of previous, on peritoneal transport, 702  
exit-site povidone-iodine ointment in prevention of, 763-768

SEP, surgery of, 456-460

Xanthomonas maltophilia peritonitis, 91-95

Permanent venous catheters, tunneled, for long-term HD vascular access, 4:A2, 4:A16

Persistent bicarbonaturia in tubular acidosis, 144

pH, *see* Primary hyperoxaluria; Primary hyperoxaluria type 1 pH  
of glucose polymer-containing PDFs, 249-251  
urinary, in tubular acidosis, 139, 141

Phagocytic activity  
effects of glucose polymer-containing PDFs on, 246-253  
rHuEPO effects on lymphocyte phenotyping and, in HD patients, 866-870

Pharmacokinetics of oral glyburide in NIDDM patients with and without ESRD, 907-911

Phenotype  
enzymic, lack of relationship between genotype, severity of PH1 and, 36-44  
rHuEPO effects on lymphocyte phenotyping and phagocyte activity in HD patients, 866-870

Phenylalanine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

PHN (passive Heymann nephritis), renoprotective properties of lisinopril in, 254-264

Phosphatase, *see* Alkaline phosphatase

Phosphate  
in ESRD, 536, 695-696  
phosphate wasting and high-bone turnover and HPT in normocalcemic long-term renal transplant recipients, 746-753

RenaGel as binder of, *see* RenaGel

serum, *see* Serum phosphate  
*see also* Ca and phosphate metabolism management in CRF and/or ESRD; Diphosphate; Hyperphosphatemia; Hyperphosphaturia; Hypophosphatemia; P

Phosphorus, *see* P

Physicians, *see* Nephrology, future aspects of; Renal physicians, supply of

Physiology of tubular acidosis, 137-140

PKD, *see* Autosomal dominant polycystic kidney disease; Polycystic kidney disease, CRF and/or ESRD and; Progression of PKD

Plasma albumin in ascitic patients, 394

Plasma calcitriol (1,25-dihydroxyvitamin D<sub>3</sub>) in nonacidotic proximal tubulopathy with hypercalciuria, 493

Plasma creatinine (Cr) in ascitic patients, 394

Plasma flow, *see* Renal plasma flow in HTN

Plasma K (potassium) in ascitic patients, 394

Plasma Na (sodium) in ascitic patients, 394

Plasma parathyroid hormone (PTH) in nonacidotic proximal tubulopathy with hypercalciuria, 493

Plasma proteins  
in ascitic patients, 394  
total, in IgAN, 530

Platelet(s)  
deposition of, on PTFE graft fistulas, effects of aspirin or ticlopidine on, 560-564  
function of, in FSGS and MCNS, 4:A3, 4:A5  
*see also* Platelet count

Platelet count  
in ARF due to postinfectious nephritis in pregnancy, 274  
in ascitic patients, 394  
in ESRD with HIVAN, 551

Platelet-derived growth factor (PDGF) A and B, and Lp effects on mesangial cell proliferation, 922-924

Pleural effusion complicating PD of ARF with HUS, 4:A1, 4:A6

PMNLs (polymorphonuclear neutrophils), *see* Neutrophil(s)

Poly[allylamine hydrochloride], *see* RenaGel

Polycystic disease, *see* Autosomal dominant polycystic kidney disease; Autosomal dominant polycystic liver disease; Polycystic kidney disease, CRF and/or ESRD and; Progression of PKD

Polycystic kidney disease (PKD), CRF and/or ESRD and in chronic HD patients, residual renal function preservation using PS dialyzers and, 581

early death prediction and in patients starting dialysis, 216  
with HCV infection, 610, 611  
with HPT, 863  
and ketoconazole effects on CRF progression, 505, 507  
quality of life and, 586, 588, 891  
rHuEPO therapy and, 653

Polycystic liver disease, autosomal dominant, portal hyper-

tension and bleeding esophageal varices due to, 4:A3, 4:A18

Polymorphonuclear neutrophils, *see* Neutrophil(s)

Polyomavirus, interstitial nephritis induced by, in renal transplant recipients, 754-758

Polyphenols, anti-oxygen free radicals of tea, for CRF, 4:A3, 4:A7

Polysulfone (PS) dialyzers, preservation of residual renal function with cellulose acetate dialyzers and, in ESRD patients on CAPD, compared, 576-583

Polytetrafluoroethylene (PTFE) graft fistulas, effects of aspirin or ticlopidine on platelet deposition on, 560-564

Population growth, and recent trends in supply of renal physicians, 784

Portal hypertension, bleeding esophageal varices and, due to ADPKD, 4:A3, 4:A18

Postdialytic symptoms, Na ramping and, 672, 673

Postural hemodilution in nephrotic edema, as cause of hemorrhage following renal biopsy, 627-630

Potassium, *see* K

Povidone-iodine ointment, exit-site, in prevention of PD-related infections, 763-768

Practice of nephrology, future, 638-639

Prealbumin, as predictor of survival in PD and HD, 4:A1, 4:A5-A6

Predialysis patients, 533-548

- CV effects of rHuEPO in, 541-548
- multidisciplinary interventions with, 533-540

Prednisone

- effects of ketoconazole and low-dose, on progression of CRF, 503-513
- for HIV-associated glomerulopathy, 4:A3, 4:A12

Preeclamptic nephropathy, ET-1 in, 345-354

Preexisting vascular disease in diabetic renal transplant candidates, 602

Pregnancy, ARF due to postinfectious GN during, 273-279

Pressure

- carbon dioxide partial, in alkaline urine in tubular acidosis, 138-139, 141
- critical renal perfusion, IRD and, 169
- oncotic, in FSGS, 147-152
- see also* Blood pressure

Prevalence

- of aPLs in SLE, 358
- of HPT, 863
- of IRD, 175
- of RAS, *see* Prevalence of RAS
- see also* specific conditions

Prevalence of RAS

- of atherosclerotic RAS in IRD, 171-173; *see also* Ischemic renal disease
- in myocardial infarction, 733-738

Prevention of PD-related infections with exit-site povidone-iodine ointment, 763-768

Previous amputation in diabetic renal transplant candidates, 605, 606

Previous peritonitis on CAPD, effects of, on peritoneal transport, 702

Primary amyloidosis, syncope with, 4:A3, 4:A18

Primary disease and attitudes toward financial incentives for kidney donation, 412, 414

in CRF and/or ESRD, *see* Primary disease in CRF and/or ESRD

- and dialysate Na effects on hypertension, 384
- and elevated serum creatinine level, 364
- in inner-city renal transplant recipients, 883
- and renal allograft survival in hypertensive African American recipients, 420
- see also* specific conditions

Primary disease in CRF and/or ESRD

- and anemia screening prior to starting rHuEPO therapy, 653
- and early death prediction in patients starting dialysis, 216
- in HCV-positive ESRD, 610, 611
- with HPT, 863
- and hypoalbuminemia on HD, 660
- in in-center HD patients, 854, 856
- preservation of residual renal function and, 578, 581
- and quality of life 3 months after start of chronic HD and/or PD, 586, 588, 589
- see also* specific conditions

Primary glomerulonephritis (GN), corticosteroid effects on lymphocytes in, 4:A3, 4:A17

Primary hyperoxaluria (PH) with renal failure, livedo reticularis, retinopathy, and peripheral neuropathy, 947-952

Primary hyperoxaluria type 1 (PH1), vertical pattern of inheritance of, 36-44

Primary renal disease in CRF, quality of life and, 891

Primary specialties among renal physicians, 782-783

PRL (prolactin), rHuEPO effects on, 4:A2, 4:A11-A12

Prognosis

- of chronic HD patients, serum cardiac troponin I and cardiac troponin T, 399-403
- of GN with proteinuria, LMW proteins and, 27-35
- IgAN, *see* Prognosis, IgAN
- see also* Outcome

Prognosis, IgAN

- prognosis of progressive renal disease in IgAN, histologic grading system and, 953-958
- renal biopsy data and, 818-819
- see also* Outcome, IgAN

Progression of (and to) CRF and/or ESRD

- early detection and management of hypertensive and diabetic renal disease in hospitalized patients preventing, 368-375
- effects of ketoconazole and low-dose prednisone on, 503-513
- of IgAN, *see* Progression of (and to) CRF and/or ESRD, IgAN
- of proteinuric GN, LMW proteins and, 27-35

Progression of (and to) CRF and/or ESRD, IgAN

- histologic grading system and, 953-958
- histologic IgAN subclassification and, 829-842

Progression of PKD

- of ADPKD, sex and effects of gonadal hormones on, 265-272
- effects of ketoconazole and low-dose prednisone on, 503-513
- paclitaxel effects on, 435-444

Progressive renal failure, rapidly, in fMf with light chain deposition disease, 942-946

Projected supply of renal physicians, 786-789

Prolactin (PRL), rHuEPO effects on, 4:A2, 4:A11-A12

Proliferative glomerulonephritis, *see* Membranoproliferative glomerulonephritis

Proliferative lupus nephritis, diffuse, PS deficiency and, 931-935

Proline in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Protein(s)

- cortical and medullary membrane, K depletion effects on, 4:A4, 4:A8-A9
- C-reactive, *see* C-reactive protein in CRF and/or ESRD patients on HD
- dietary, *see* Dietary protein intake
- fusion, costimulatory signals and, in immunosuppression, 311
- LMW, in GN with proteinuria, clinical significance and prognostic value of, 27-35
- plasma, *see* Plasma proteins
- total, *see* Total proteins
- see also* Protein catabolic rate on HD; Protein S deficiency; Proteinuria

Protein catabolic rate (PCR) on HD

- and Ab response to HBV vaccine, 240
- normalized, 3 months after start of chronic HD and/or PD, 586, 589

Protein S (PS) deficiency, DPLN and, 931-935

Proteinuria

- in arteriolar sclerosis, 914
- in CRF, *see* Proteinuria in CRF
- in FSGS with NS in cholesterol atheroembolism, 334-344
- in GN, SDS-PAGE in characterization of, 27-35
- in hospitalized hypertensive and diabetic patients, 370, 371
- in IgAN, 527, 528, 530
- in IMN, 201, 202
- influence of dietary NaCl on antiproteinuric effects of Ca channel blockers, 800-805
- in membranous nephropathy, 116
- myocardial infarction, renal artery stenosis and, 734
- in nonacidotic proximal tubulopathy with hypercalcemia, 493
- secondary to bilateral renal vein thrombosis, systemic thrombolytic therapy of, 615-619
- see also* Albuminuria

Proteinuria in CRF

- ketoconazole plus low-dose prednisone effects on, 503-513
- and rHuEPO in predialysis CRF patients, 543

Proton-pump inhibitor, amoxicillin and, in eradication of *H. pylori* in ESRD patients on dialysis, 86-90

Protoporphyrin, zinc, in ESRD, 325

Proximal tubular acidosis, isolated, 143

Proximal tubular cells, isoflurane effects on energetics of, 4:A1, 4:A12

Proximal tubules

- fluid and electrolyte transport by, ET effects on, 8-10
- fractional solute reabsorption by, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114
- see also* Proximal tubulopathy and entries beginning with terms: Proximal tubular

Proximal tubulopathy, nonacidotic autosomal dominant, 490-495

PS (polysulfone) dialyzers, preservation of residual renal function with cellulose acetate dialyzers and, in ESRD patients on CAPD, compared, 576-583

PS (protein S) deficiency, DPLN and, 931-935

Pseudodominant (vertical) pattern of PH1 inheritance, 36-44

Pseudopulmonary embolism in heparin-induced thrombocytopenia and thrombosis, 449-452

PTFE (polytetrafluoroethylene) graft fistulas, effects of aspirin or ticlopidine on platelet deposition on, 560-564

PTH, *see* Parathyroid hormone

PTRA, *see* Percutaneous transluminal renal angioplasty

Pulmonary mucormycosis in diabetic renal transplant recipients, 461-464

Pulse calcitriol (1,25-dihydroxyvitamin D<sub>3</sub>) in advanced secondary HPT, 4:A1, 4:A6-A7

Pulse oxymetry of O<sub>2</sub> saturation in upper extremity with AV fistula before and after HD, 230-232

Purpura, *see* Henoch-Schönlein purpura

Pyelonephritis, chronic, ESRD and, 660

Quality of care

- early detection and management of hypertensive and diabetic renal disease in hospitalized patients and, 368-375
- improvement in delivery of in-center HD for ESRD as indicator of, 851-861

Quality of life of CRF and/or ESRD patients

- MDRD study of, 888-896
- 3 months after start of chronic HD and/or PD, 584-592
- Quality of Well-Being Scale (QWB) used in MDRD study of CRF patients, 888-896

Race and ethnicity

- and attitudes toward financial incentives for kidney donation, 412, 414
- of CRF and/or ESRD patients on dialysis, 216, 686; *see also* Race and ethnicity of CRF and/or ESRD patients on CAPD and/or HD
- and familial clustering of ESRD with lupus nephritis and, 729-732
- hypertension and, *see* Hypertension, race and
- of ICGN patients with HIV and HCV infections, 516
- of IgAN patients, 201, 526-532
- of IMN patients, 201
- of inner-city renal transplant recipients, 882
- and renal response to chronic fosinopril and/or lisinopril therapy in older hypertensive patients with chronic renal insufficiency, 897-906
- sex and, and risk of ESRD with diabetic nephropathy, 4:A3, 4:A19-A20
- SLC associated with insulin resistance and albuminuria and, 45-53
- of SLE patients, aPLs and, 357
- and vasectomy as risk factor for urolithiasis, 209

Race and ethnicity of CRF and/or ESRD patients on CAPD and/or HD

- ABPM and, 679
- with HIVAN, 550
- with HPT, 863
- of hyperphosphatemic CRF patients, 68
- and hypoalbuminemia on HD, 660
- on in-center HD, 854, 856

positive for HCV, 610, 611

Radicals, *see* Free radicals

Radiocontrast dye nephropathy, ETs in, 13-14

Rapamycin (sirolimus), 307

Rapidly progressive renal failure in fMF with light chain deposition disease, 942-946

RAS, *see* Renal artery stenosis

Rationing of dialysis for ESRD, early death and, 214-222

RBF, *see* Renal blood flow

Reactive oxygen metabolites, *see* Oxidants in toxic ARF

Recirculation, vascular access

- relationship of, to BF, 223-229
- urea sampling measuring, in HD of ARF, 4:A1, 4:A10-A11

*see also* Recirculation in peripheral AV versus CVV access

Recirculation in peripheral AV versus CVV access, 479-484

AV disequilibrium, cardiopulmonary recirculation, dialysis

- delivery and, 483-484
- in CVV access, 479-481
- with CVV catheters, 483
- with femoral vein catheters, 480
- lime reversal and, 482-483
- in peripheral AV access, 480-482

Recombinant human erythropoietin (rHuEPO)

- cardiovascular effects of, in predialysis CRF patients, 541-548
- reproductive and gynecologic issues in women on dialysis, 686; *see also* Recombinant human erythropoietin for CRF and/or ESRD patients on CAPD and/or HD

Recombinant human erythropoietin (rHuEPO) for CRF and/or ESRD patients on CAPD and/or HD

ABPM of CAPD patients, 679

cost-effectiveness of anemia screening prior to starting, 651-657

effects of, on Ab response to HBV vaccine, 241

effects of, on lymphocyte phenotyping and phagocyte activity, 866-870

effects of, on PRL levels, hypogonadism, and bone density, 4:A2, 4:A11-A12

Fe and, *see* Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy

interaction between enalapril and, in chronic HD patients, 4:A2, 4:A18

resistance to, *see* Resistance to rHuEPO therapy

Recurrence

- of ANCA-associated vasculitis following renal transplantation, 96-102
- of IgAN with IgA ANCs following renal transplantation, 125-131
- of NS, minimal change NS, FSGS, C1q nephropathy and, 966-970

Red cell ferritin in ESRD, 323

Regional blood flow (BF) model in peripheral AV versus CVV access

- defined, 488
- venovenous disequilibrium and, 484-486

Regional databank on IgAN renal biopsy, 818

Rehabilitation of chronic HD patients, 4:A2, 4:A21

Rejection, acute renal graft, IL-8 expression following renal transplantation and, 871-880

Relapse, *see* Recurrence

Relatives, *see* Families

Relaxation, MC, in GFR regulation, 975-976

RenaGel (poly[allylamine hydrochloride])

- effects of, on serum P and PTH in HD patients, 4:A1, 4:A6 as noncalcemic phosphate binder for hyperphosphatemia in CRF, 66-71

Renal allograft rejection, IL-8 expression following renal transplantation and, 871-880

Renal allograft survival, 419-434

- CMV infection effects on, 428-434
- relationship between hypertension and, race and, 419-427

Renal angioplasty, *see* Percutaneous transluminal renal angioplasty

Renal artery stenosis (RAS)

- in elderly patients, SCR following PTRA of, 4:A4, 4:A11
- prevalence of, *see* Prevalence of RAS
- unilateral FSGS and, 936-941

Renal artery stents for IRD, 181-182

Renal biopsy

- hemorrhage following, postural hemodilution in nephrotic edema as cause of, 627-630
- in ICGN with HIV and HCV infections, 516, 517
- in IgAN, *see* Renal biopsy in IgAN
- in nephrotic syndrome with hematuria and renal insufficiency, 806-810
- of preeclamptic nephropathy, 345-354
- of relapsing NS, 966-967
- see also* Histology and histopathology and specific conditions

Renal biopsy in IgAN

- indication for, 527
- see also* Histology and histopathology, IgAN; Renal biopsy data on IgAN, management of

Renal biopsy data on IgAN, management of, 817-828

- administrative issues related to, 823-824
- and clinicopathologic correlations from IgAN database of Mayo Nephrology Collaborative Group, 820-821
- conclusions and recommendations on, 824-826
- and histologic gradation of biopsy specimens, 821-822
- IgAN prognosis and, 818-819
- issues related to database development in, 822-823
- progress on regional databank and, 818
- scoring systems and, 819-820, 825

Renal blood flow (RBF)

- of hypertensive patients, endogenous EPO and, 377
- see also* Renal blood flow, ET-1 and

Renal blood flow (RBF), ET-1 and, 4

- in ischemic renal failure, 12
- in toxin-related renal injury, 14

Renal cortical mitochondria

- gentamicin effects on production of  $H_2O_2$  by, 467
- gentamicin-induced Fe mobilization from, 467-468

Renal disease and disorders

- effects, on mesangial cell tone, GFR regulation and, 976-977
- ETs in, 12-17
- see also* specific conditions

Renal failure, 942-952

- primary hyperoxaluria with livedo reticularis, retinopathy, and peripheral neuropathy, 947-952
- rapidly progressive, in fMF with light chain deposition disease, 942-946

severe hyperphosphatemia following phosphate administration for bowel preparation in patients with, 103-105  
*see also* Acute renal failure; Chronic renal failure; Ischemic renal failure

Renal function  
bone density and metabolism with reduced, 4:A3, 4:A9 in CRF and/or ESRD, *see* Renal function in CRF and/or ESRD  
with IgAN, 527  
with IRD, surgical retrieval of, 179-180  
lisinopril effects on, in membranous nephropathy, 257-258  
*see also* Renal insufficiency; Renal sufficiency *specific aspects of renal function and specific conditions*  
Renal function in CRF and/or ESRD  
on CAPD, preservation of residual with polysulfone dialyzers in, 576-583  
3 months after start of chronic HD and/or PD, 586, 588-589

Renal hemodynamics  
monitoring of, in ARF management, 794  
*see also* Glomerular filtration rate; Hyperfiltration; Renal blood flow; Renal plasma flow in HTN

Renal injury, toxin-related, ETs in, 12-14

Renal insufficiency  
chronic, *see* Chronic renal insufficiency in the elderly  
myocardial infarction, renal artery stenosis and, 734  
in PKD, paclitaxel effects on, 435-444

Renal osteodystrophy, *see* Bone disease

Renal perfusion pressure, critical, IRD and, 169

Renal physicians, supply of, 781-792  
AMA Physician Masterfile and, 781-782  
current supply, 782-784  
and future utilization of nephrology services, 789-790  
projected supply, 786-789  
recent trends in, 784-785

Renal plasma flow (RPF) in HTN  
in elderly hypertensive patients with chronic renal insufficiency, effects of chronic ACE inhibition on, 900-902  
endogenous EPO and, 377

Renal replacement therapy (RRT)  
continuous, for ARF, 796  
*see also* Dialysis; Renal transplantation

Renal resistance vessels, ETs in, 4-6

Renal response to chronic fosinopril and/or lisinopril therapy  
in older hypertensive patients with chronic renal insufficiency, racial differences in, 897-906

Renal sufficiency, nephrotic syndrome with hematuria and, renal biopsy of, 806-810

Renal survival in IgAN, 529-530  
histologic subclassification and, 833

Renal transplantation, 593-614  
ABPM in recipients of, 593-600  
ANCA following, *see* Antineutrophil cytoplasmic antibodies following renal transplantation  
changes in eating behavior following, 691-698  
CMV infection effects on survival with, 428-434  
in diabetic patients, *see* Renal transplantation in diabetic patients  
effects of, on HCV-positive ESRD patient survival, 608-614

for fMF with light chain deposition disease, 942-946  
IL-8 expression following, as predictor of rejection, 871-880

normocalcemic long-term recipients of, high-bone turnover and HPT in, 746-753

in patients with malignant disease, *see* Renal transplantation in patients with malignant disease

polyomavirus-induced interstitial nephritis in recipients of, 754-758

for primary hyperoxaluria with renal failure, livedo reticularis, retinopathy, and peripheral neuropathy, 947-952

unemployment among inner-city recipients of, 881-887  
*see also* Clinical studies and trials of new immunosuppressive agent(s); Donors

Renal transplantation in diabetic patients, 420  
atherosclerotic vascular complications in, 601-607  
pulmonary mucormycosis in, 461-464

Renal transplantation in patients with malignant disease  
retransplantation, 4:A4, 4:A15-A16  
with thyroid cancer, 4:A4, 4:A14  
with transitional cell carcinoma, 4:A4, 4:A15

Renal tubules, *see* Tubules

Renal ultrasound for elevated serum creatinine level, 362-367

Renal vascular resistance, chronic lisinopril and/or fosinopril effects on, 901

Renal vasculature, ET-1 in, 4-6  
ET-1-induced constriction of, 5-6  
ET-1 production by, 4  
ET-1 receptors in, 4-5

Renal vein thrombosis (RVT), bilateral, systemic thrombolytic therapy of proteinuria secondary to, 615-619

Renal weight in ADPKD, 267, 268

Renal work notion, history of, 777-780

Renin, postural hemodilution in nephrotic edema and, 628

Renin-angiotensin system, expression of components of, in diabetes, 154-156

Renoprotective properties of lisinopril in membranous nephropathy, 254-264

Reproduction by women on dialysis, 685-690

Research, future nephrology, 637

Residual glomerular filtration rate (rGFR) 3 months after start of chronic HD and/or PD for CRF and/or ESRD, 586, 589

Residual renal function, polysulfone dialyzers and preservation of, in ESRD patients on CAPD, 576-583

Resistance, *see* Insulin resistance; Resistance to rHuEPO therapy

Resistance to rHuEPO therapy  
causes of, 320  
C-reactive protein as predictor of, 565-568  
in ESRD with heterozygous hemoglobinopathy J-Meinung, 769-772

Respiratory distress, acute, in heparin-induced thrombocytopenia and thrombosis, 449-452

Retinopathy, primary hyperoxaluria with renal failure, livedo reticularis, and peripheral neuropathy, 947-952

Retransplantation in patient with malignant disease, 4:A4, 4:A15-A16

Revascularization, surgical, in dialysis-dependent IRD, 180

rGFR (residual glomerular filtration rate) 3 months after start

of chronic HD and/or PD for CRF and/or ESRD, 586, 589

Rheumatoid arthritis in relatives of lupus nephritis patients, 731.

rHuEPO, *see* Recombinant human erythropoietin

Ribonucleic acid (RNA)

- ECM messenger, effects of lisinopril on expression of, in PHN, 259
- HCV, in ICGN with HIV and HCV infections, 516
- Rickets, nonacidotic proximal tubulopathy compared with, 493

Risk factor(s)

- for atherosclerotic RAS in IRD, 173
- for CRF and/or ESRD, race, sex, diabetic nephropathy and, 4:A3, 4:A19-A20
- for hospitalization of HD patients, 4:A1, 4:A7-A8
- for IgAN, 526-532
- Lp(a) and other cardiovascular, in CRF and/or ESRD patients on dialysis, 4:A2, 4:A13
- vasectomy as, for urolithiasis, 207-213

*see also specific risk factors*

RNA, *see* Ribonucleic acid

RPF, *see* Renal plasma flow in HTN

RRT, *see* Renal replacement therapy

RS-61443 (mycophenolate mofetil), 309-310

RVT (renal vein thrombosis), bilateral, proteinuria secondary to, systemic thrombolytic therapy of, 615-619

*S aureus* (*Staphylococcus aureus*) carriers, PD-related infections in nasal, 763-768

SAA (serum amyloid A), and albumin concentrations in ESRD patients on HD, 658-668

Salt, dietary, influence of, on antiproteinuric effects of Ca channel blockers, 800-805

Saphenous vein endothelial cells, human, serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85

SBP (systolic blood pressure), *see* Blood pressure

SCL-90R (Symptom Checklist-90R) used in MDRD study of CRF patients, 888-896

Sclerosing encapsulating peritonitis (SEP), surgery of, 456-460

Sclerosis

- myofibroblasts and arteriolar, in diabetic nephropathy, 912-918
- see also* Glomerulosclerosis; Nephrosclerosis; Sclerosing encapsulating peritonitis and entries beginning with term: Atherosclerotic

Scoring systems for IgAN, 819-820, 825

SCr, *see* Serum creatinine

Screening, anemia, prior to starting rHuEPO therapy of ESRD patients, cost-effectiveness of, 651-657

SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis), proteinuria in GN characterized with, 27-35

Secondary hyperparathyroidism, *see* Calcitriol for secondary HPT; Hemodialysis for secondary HPT

Secondary specialties among renal physicians, 782-783

Segmental glomerulosclerosis, *see* Focal segmental glomerulosclerosis

Segmental necrotizing glomerulonephritis (GN), P-ANCA-associated pauci-immune, membranous lupus nephritis with, 119-124

Selectin, and monocyte and granulocyte adherence to HSVECs during HD, 78-85

Self-care continuous ambulatory peritoneal dialysis (CAPD), HHD for, patients trained in, 4:A1, 4:A10

SEP (sclerosing encapsulating peritonitis), surgery of, 456-460

Serine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Sertraline hydrochloride, effect of, on HD hypotension, 4:A1, 4:A8

Serum albumin

- in ARF due to postinfectious GN during pregnancy, 274
- in CRF and/or ESRD, *see* Serum albumin in CRF and/or ESRD
- in ICGN with HIV and HCV infections, 516
- in IMN, 201-203
- in long-term renal transplant recipients, 747, 749
- in membranous nephropathy, 116
- and quality of life in chronic dialysis patients, 589

Serum albumin in CRF and/or ESRD

- with HIVAN, 549-552
- quality of life and, 891
- rHuEPO resistance and, 567
- with SLE, 731
- starting dialysis, 219
- 3 months after start of chronic HD and/or PD, 586, 589

Serum aluminum (Al) in CRF and/or ESRD

- rHuEPO resistance and, 567
- screening for concentrations of, prior to starting rHuEPO therapy, 652

Serum amyloid A (SAA), and albumin concentrations in ESRD patients on HD, 658-668

Serum BUN (blood urea nitrogen) in ARF due to postinfectious nephritis in pregnancy, 274

Serum Ca (calcium)

- in hyperparathyroidic ESRD patients on HD, 862-865
- nifedipine effects on, 234
- total, in long-term renal transplant recipients, 747, 749

Serum calcitriol [1,25-(OH<sub>2</sub>)D<sub>3</sub>] in long-term renal transplant recipients, 747, 749

Serum cardiac troponin I (cTnI) and cardiac troponin T (cTnT), prognosis of chronic HD patients and, 399-403

Serum Cl (chloride)

- in ARF due to postinfectious GN during pregnancy, 274
- effects of P-enriched conventional Ca-containing dialysis solution on, 289

Serum creatinine (SCr)

- in ARF due to postinfectious nephritis in pregnancy, 274
- in arteriolar sclerosis, 914
- in CRF and/or ESRD, 505, 551, 891
- effects of antihypertensive therapy on, race and, 723
- in elderly hypertensive patients with chronic renal insufficiency, effects of chronic ACE inhibition, 900

following PTCA of elderly ischemic nephropathy patients, 4:A4, 4:A11

- in FSGS with NS in CAE, 336
- in hospitalized hypertensive diabetic patients, 370, 371
- in ICGN with HIV and HCV infections, 516

in IgAN, 530, 833  
 in IMN, 201, 202  
 P-enriched conventional Ca-containing dialysis solution effects on, 289  
 in preeclampsia, 347  
 in proteinuric GN, 29-31  
 in renal transplant recipients, *see* Serum creatinine in renal transplant recipients  
 renal ultrasound for elevated, 362-367  
 in SLE, 731  
 Serum creatinine (SCr) in renal transplant recipients  
 in long-term renal transplant recipients with high-bone turnover and HPT, 747, 749, 750  
 and renal allograft function in hypertensive recipients, race and, 423  
 Serum factors inhibiting adherence of monocytes and granulocytes to human saphenous endothelial cells during HD, 78-85  
 Serum Fe (iron), screening for, prior to starting rHuEPO therapy of ESRD patients, 652  
 Serum ferritin in CRF and/or ESRD, 322-324  
 red cell, 324  
 rHuEPO resistance and, 567  
 Serum gastrin following *H pylori* eradication in dialyzed ESRD patients, 87-88  
 Serum glutamate pyruvate transaminase, *see* Alanine transaminase  
 Serum glutamic-oxaloacetic transaminase, *see* Aspartate transaminase  
 Serum H<sub>2</sub>CO<sub>3</sub> (bicarbonate) in ESRD with HPT, 864  
 Serum 25-hydroxycholecalciferol [25(OH)D] in long-term renal transplant recipients, 747, 749  
 Serum K (potassium)  
 in ARF due to postinfectious GN during pregnancy, 274  
 effects of P-enriched conventional Ca-containing dialysis solution on, 289  
 in hypokalemic metabolic alkalosis with hypomagnesuria and severe hypocalciuria, 108  
 Serum lipids, androgen effects on levels of, in chronic HD patients, 569-575  
 Serum lipoprotein(a) [Lp(a)], nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575  
 Serum Mg (magnesium) in hypokalemic metabolic alkalosis with hypomagnesuria hypermagnesemia and severe hypocalciuria, 108  
 Serum Na (sodium)  
 in ARF due to postinfectious GN during pregnancy, 274  
 effects of P-enriched conventional Ca-containing dialysis solution on, 289  
 Serum osteocalcin, and high-bone turnover and HPT in normocalcemic long-term renal transplant recipients, 746-753  
 Serum P (phosphorus)  
 in ESRD with HPT, 864  
*see also* Serum P in HD patients  
 Serum P (phosphorus) in HD patients  
 nifedipine effects on, 234  
 RenaGel effects on, 4:A1, 4:A6  
 Serum parathyroid hormone (PTH)  
 in HD, *see* Serum parathyroid hormone, HD and in long-term renal transplant recipients, 747, 749  
 Serum parathyroid hormone (PTH), HD and in CRF patients, rHuEPO resistance and, 567  
 nifedipine effects on, 234  
 RenaGel effects on, 4:A1, 4:A6  
 Serum phosphate  
 in hyperparathyroidic ESRD patients on HD, 862-865  
 in long-term renal transplant recipients, 747, 749  
 Serum transferrin in CRF patients on HD, rHuEPO resistance and, 567  
 Serum urea nitrogen  
 in ADPKD, 267, 268  
 in CRF, 505  
 effects of P-enriched conventional Ca-containing dialysis solution on, 289  
 Serum uric acid in ARF due to postinfectious GN during pregnancy, 274  
 Severe hyperphosphatemia following phosphate administration for bowel preparation in renal failure patients, 103-105  
 Severe hypertension (HTN) secondary to systemic entomophthoromycosis, 620-623  
 Severe hypocalcemia and hypophosphatemia (hungry bone syndrome) following parathyroidectomy for secondary HPT in ESRD patients on HD, 759-762  
 Severe hypocalciuria, hypokalemic metabolic alkalosis with hypomagnesuria hypermagnesemia and, 106-114  
 Severe hypophosphatemia  
 isolated hyperphosphaturia and, with multiple myeloma, 445-448  
 severe hypocalcemia and, following parathyroidectomy for secondary HPT in ESRD patients on HD, 759-762  
 Severity of disease  
 of PH1, lack of relationship between genotype and, 36-44  
*see also* entries beginning with term: Severe  
 Sex  
 and attitudes toward financial incentives for kidney donation, 412, 414  
 body weight and, and nephrosclerosis, 4:A4, 4:A16  
 of children with biliary atresia, 189  
 of CRF and/or ESRD patients, 505, 731, 891; *see also* Sex of CRF and/or ESRD patients on CAPD and/or HD of FSGS patients with NS in CAE, 336  
 and gonadal hormone effects on progression of ADPKD, 265-272  
 of hypertensive patients, 370, 384, 420  
 of ICGN patients with HIV and HCV infections, 516  
 of IgAN patients, 528, 533  
 of IMN patients, 201  
 of myocardial infarction patients with renal artery stenosis, 734  
 of NIDDM patients, 908  
 of primary amyloidosis patients presenting with syncope, 4:A3, 4:A18  
 race and, and risk of ESRD with diabetic nephropathy, 4:A3, 4:A19-A20  
 of renal physicians, 783, 785, 787, 789  
 of renal transplant recipients, *see* Sex of renal transplant recipients  
 of SLE patients, aPLs and, 357  
*see also* Women and specific conditions

Sex of CRF and/or ESRD patients on CAPD and/or HD and Ab response to HBV vaccine, 240

ABPM and, 594, 679

and dialysate Na effects on hypertension, 384

of dyslipidemic patients, 55

and effects of exit-site povidone-iodine ointment on infections, 764

having developed SLE 14 years after commencing HD, 631-632

with HIVAN, 550

with HPT, 863

of hyperphosphatemic patients, 68

on in-center HD, 854, 856

on nifedipine therapy, 234

positive for HCV, 610, 611

preservation of residual renal function and, 578

and quality of life 3 months after start of chronic HD, 586, 588

and resistance to rHuEPO, 566

starting dialysis, early death and, 216

Sex of renal transplant recipients

diabetic, atherosclerotic vascular complications and, 602, 605

hypertensive, renal allograft survival and, 420

of inner-city recipients, 882

long-term recipients, high-bone turnover and HPT in, 747, 749, 750

Sexuality, effects of dialysis for ESRD on women's, 685-690

SGOT (serum glutamic-oxaloacetic transaminase), *see* Aspartate transaminase

SGPT (serum glutamate pyruvate transaminase), *see* Alanine transaminase

Short-bowel syndrome, calciphylaxis and, 773-776

Short-term effects of antihypertensive therapy on GFR, race and, 720-728

Silicon dual-lumen catheters, long-term vascular access for HD using, with guidewire replacement of catheters, 553-559

Sirolimus (rapamycin), 307

Sixth annual spring nephrology meetings (April 17-20, 1997), abstracts of, 4:A1-A21

SKF-105685, 311

Skin fibroblasts, collagen mRNA in, in IDDM nephropathy patients, 4:A4, 4:A20

SLC (sodium-lithium countertransport) associated with insulin resistance and albuminuria in young African Americans, 45-53

SLE, *see* Systemic lupus erythematosus

Slow-flow/stop-flow recirculation method, defined, 488

Smoking

- by CRF patients, quality of life and, 891
- by diabetic renal transplant candidates, atherosclerotic vascular complications and, 602
- by FSGS patients with NS in CAE, 336
- myocardial infarction, renal artery stenosis and, 734
- as risk factor for presence of atherosclerotic RAS in IRD, 173

Sodium, *see* Na

Sodium chloride (NaCl), dietary, influence of, on antiproteinuric effects of Ca channel blockers, 800-805

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), proteinuria in GN characterized with, 27-35

Sodium-lithium countertransport (SLC) insulin resistance and albuminuria associated with, race and, 45-53

Soft tissue calcification due to Ca and phosphate overload in ESRD, 645-646

Soluble transferrin receptor in ESRD, 325

Specialties, primary and secondary, among renal physicians, 782-783

*Staphylococcus aureus (S. aureus)* carriers, PD-related infections in nasal, 763-768

Stenosis, *see* Renal artery stenosis

Stents, renal artery, for IRD, 181-182

Steroids, *see* Corticosteroids

Stones, *see* Nephrolithiasis; Urolithiasis

Subclassification, histologic IgAN, 829-842

Superoxide ( $O_2^-$ ), effects of glucose polymer-containing PDFs on, 249-250

Supplementation, Ca and/or vitamin D, in HPT, 863

Supply of renal physicians, *see* Renal physicians, supply of

Surgery

- of IRD, 179-182
- parathyroidectomy for secondary HPT in HD patients, 759-762
- percutaneous mechanical thrombectomy for AV fistula salvage, 4:A1, 4:A9
- of SEP, 456-460
- vasectomy as risk factor for urolithiasis, 207-213
- see also* Percutaneous transluminal renal angioplasty

Survival, *see* Patient survival; Renal allograft survival; Renal survival in IgAN

Symptom(s), 671-673

- intradialytic, Na ramping and, 671-672
- postdialytic, Na ramping and, 672, 673
- uremic, correlated with quality of life, 888-896
- see also* Clinical features and presentation and specific conditions

Symptom Checklist-90R (SCL-90R) used in MDRD study of CRF patients, 888-896

Syncope with primary amyloidosis, 4:A3, 4:A18

Systemic entomophthoromycosis, severe hypertension secondary to, 620-623

Systemic lupus erythematosus (SLE)

- development of, 14 years after start of HD for ESRD, 631-632
- family clustering of ESRD in African Americans with, 729-732
- with membranous GN and uterine vasculitis, 277-279
- pediatric, aPLs in, 355-361
- see also* Lupus nephritis

Systemic thrombolytic therapy of proteinuria secondary to bilateral renal vein thrombosis, 615-619

Systolic blood pressure, *see* Blood pressure

Table salt (sodium chloride), influence of, on antiproteinuric effects of Ca channel blockers, 800-805

Tacrolimus, *see* FK-506

Taurine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Taxol (paclitaxel), effects of, on progression of PKD, 435-444

Tea polyphenols, anti-oxygen free radicals of, for CRF, 4:A3, 4:A7

Testosterone, sex and effects of, on progression of ADPKD, 265-272

TG(s), *see* Triglyceride(s)

TGF- $\beta$ , *see* Transforming growth factor- $\beta$

Therapy and management of ANCA-associated vasculitis, 97

antibiotic, *see* Antibiotics

antihypertensive, *see* Antihypertensive therapy

anti-oxygen tea polyphenol free radical, for CRF, 4:A3, 4:A7

with apheresis, pseudopulmonary embolism in heparin-induced thrombocytopenia and, 449-452

of ARF, *see* Acute renal failure, management and outcome of

of ascites, 392-398

aspirin or ticlopidine, effects of, on platelet deposition on PTFE graft fistulas, 560-564

calcitonin, effects of, on low-turnover bone disease in HD patients, 4:A2, 4:A19

calcitriol, *see* Calcitriol

of chronic metabolic acidosis, 300

corticosteroid, *see* Corticosteroids

early, of renal disease in diabetic and hypertensive patients, 368-375

estrogen replacement, for dialyzed women, 685-690

exit-site povidone-iodine ointment, in prevention of PD-related infections, 763-768

of fMF with light chain deposition disease, 942-946

immunosuppressive, *see* Clinical studies and trials of new immunosuppressive agent(s) and specific immunosuppressive agents

$\alpha$ -interferon, of fibrillary GN associated with HCV infection, 132-135

of IRD, 179-182

lithium, *see* Lithium

lupus nephritis, 193-199

MMC, endotheliopathy as continuum of HUS due to, 280-284

multidisciplinary, of predialysis patients, 533-540

nifedipine, effects of discontinuation of, on cytosolic Ca, and B cell proliferation in CRF patients on HD, 233-238

nonpharmacological, renal work notion and introduction of, 777-780

nutritional, *see* Chronic renal failure, nutrition in; Supplementation; Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy

entries beginning with terms: Dietary, Parenteral

oral glyburide, in NIDDM patients with and without ESRD, pharmacokinetics of, 907-911

paclitaxel, effects of, on progression of PKD, 435-444

of proteinuric GN, 33

RenaGel, *see* RenaGel

renal replacement, *see* Renal replacement therapy of severe hypocalcemia, 761-762

surgical, *see* Surgery

systemic thrombolytic, of proteinuria secondary to bilateral renal vein thrombosis, 615-619

of *Xanthomonas maltophilia* peritonitis, 92, 93

*see also* Ca and phosphate metabolism management in CRF and/or ESRD and specific conditions

Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy

and Fe saturation after initiation or cessation of rHuEPO, 4:A1, 4:A10

with oral iron, 325-326

with parenteral iron, 326-329

strategies for, 329-330

Three-needle recirculation method, defined, 488

Threonine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Thrombectomy, percutaneous mechanical, AV fistula salvage with, 4:A1, 4:A9

Thrombocytopenia, heparin-induced, pseudopulmonary embolism and, 449-452

Thrombolytic therapy, systemic, of proteinuria secondary to bilateral renal vein thrombosis, 615-619

Thrombosis

heparin-induced, pseudopulmonary embolism and, 449-452

with pediatric SLE, aPLs and, 355-361

proteinuria secondary to bilateral renal vein, systemic thrombolytic therapy of, 615-619

Thyroid cancer in renal transplant recipients, 4:A4, 4:A14

Ticlopidine, effects of, on platelet deposition on PTFE graft fistulas, 560-564

Time on CAPD and/or HD, 578

and Ab response to HBV vaccine, 240

CRP, rHuEPO resistance and, 566

development of SLE 14 years after commencing HD, 631-632

effects of, on peritoneal transport, 702

nifedipine therapy and, 234

Time on dialysis

and attitudes toward financial incentives for kidney donation, 412

of ESRD women, reproductive and gynecologic issues and, 686

for HCV-positive ESRD, 610, 611

of inner-city renal transplant recipients, 883

*see also* Time on CAPD and/or HD

Tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA (messenger ribonucleic acid) in skin fibroblasts of IDDM nephropathy patients, 4:A4, 4:A20

TNF- $\alpha$  (tumor necrosis factor- $\alpha$ ), and Lp effects on mesangial cell proliferation, 925-926

Tone, MC, effects of disease on, GFR regulation and, 976-977

Total Ca (calcium)

effects of P-enriched conventional Ca-containing dialysis solution on, 289

serum, in long-term renal transplant recipients, 747, 749

Total cholesterol in diabetic renal transplant candidates, 602

Total CO<sub>2</sub> (carbon dioxide) in ARF due to postinfectious nephritis in pregnancy, 274

Total proteins  
 plasma, in IgAN, 530  
 postural hemodilution in nephrotic edema and, 628

Toxic acute renal failure, *see* Oxidants in toxic ARF

Toxin-related renal injury, ETs in, 12-14

Training  
 future nephrologist, 633-636  
*see also* Education

Transaminase, *see* Alanine transaminase; Aspartate transaminase

Transferrin in CRF and/or ESRD  
 saturation of, 323-324  
 screening for concentrations of, prior to starting patients  
 on rHuEPO therapy, 652  
 serum, in patients on HD, rHuEPO resistance and, 567

Transferrin receptor, soluble, in ESRD, 325

Transforming growth factor- $\beta$  (TGF- $\beta$ )  
 in diabetic nephropathy, 153-163  
 lisinopril effects on, in membranous nephropathy, 254-264  
 and Lp effects on mesangial cell proliferation, 925

Transitional cell carcinoma in renal transplant recipients, 4:A4, 4:A15

Transluminal renal angioplasty, *see* Percutaneous transluminal renal angioplasty

Transpeptidase, gamma-glutamyl, in HCV-positive ESRD patients, 610, 611

Transplantation, *see* Renal transplantation

Triglyceride(s) (TGs)  
 in CRF, 57, 60  
 in diabetic renal transplant candidates, 602  
 SLC, albuminuria and, 49, 50

Triglyceride-rich lipoproteins (TG Lps), effects of, on mesangial cell proliferation, 919-930

Trimethoprim-sulfamethoxazole, hyperkalemia and, 959-965

Troponin I and troponin T, serum cardiac, and prognosis of chronic HD patients, 399-403

Tubular acid secretion in chronic metabolic acidosis, 294-296

Tubular acidosis  
 classification of, 136-146  
 and nonacidotic proximal tubulopathy with hypercalcuria, 493

Tubular cells, proximal, isoflurane effects on energetics of, 4:A1, 4:A12

Tubular cysts due to chronic lithium ingestion, 4:A3, 4:A5

Tubular growth in chronic metabolic acidosis, 296-297

Tubular necrosis, acute, acute allograft rejection and, and IL-8 expression following renal transplantation, 871-880

Tubular (low molecular weight) proteins in GN with proteinuria, clinical significance and prognostic value of, 27-35

Tubules  
 ETs in, 7-11  
 proximal, *see* Proximal tubules  
*see also* entries beginning with term: Tubular and element: Tubulo-

Tubulointerstitial damage in proteinuric GN, 30, 31

Tubulopathy, nonacidotic proximal autosomal dominant, 490-495

Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and Lp effects on mesangial cell proliferation, 925-926

Tunnel infections, catheter with, removal and replacement of, 706-711

Tunneled permanent venous catheters for long-term HD vascular access, 4:A2, 4:A16

Twins, identical, idiopathic membranous nephropathy in, 115-118

Two-needle recirculation method, defined, 488

Type I diabetes mellitus (insulin-dependent diabetes mellitus), *see* Diabetes mellitus

Type I primary hyperoxaluria (PH1), vertical pattern of inheritance of, 36-44

Type II diabetes mellitus (non-insulin-dependent diabetes mellitus), *see* Diabetes mellitus

Tyrosine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Ultrasound, renal, for elevated serum creatinine level, 362-367

Unemployment among inner-city renal transplant recipients, 881-887

Unilateral focal segmental glomerulosclerosis (FSGS), RAS and, 936-941

Universal eating monitor (VIKTOR), eating behavior changes in ESRD patients on CAPD and after renal transplantation monitored with, 691-698

Upper extremity, pulse oxymetry of O<sub>2</sub> saturation in, with AV fistula before and after HD, pulse oxymetry of, 230-232

Urea  
 blood, and vascular access BF, 224  
 clearance of, *see* Urea clearance on CAPD for ESRD  
 Na ramping and reduction of, 671  
 sampling of, to measure vascular access recirculation in HD of ARF, 4:A1, 4:A10-A11  
*see also* Urea reduction ratio

Urea clearance on CAPD for ESRD  
 before and after CAPD, 695  
 cellulose acetate versus PS dialyzers and, 581

Urea nitrogen  
 blood, *see* BUN  
 following *H pylori* eradication in ESRD patients on dialysis, 87-88  
 postural hemodilution in nephrotic edema and, 628  
 serum, *see* Serum urea nitrogen

Urea reduction ratio (URR)  
 with HD of CRF and/or ESRD, *see* Urea reduction ratio with HD of CRF and/or ESRD  
 with peripheral AV versus CVV dialysis access, 487-488  
*see also* Kt/V

Urea reduction ratio (URR) with HD of CRF and/or ESRD and HIVAN, 549-552  
 of hyperparathyroidic ESRD, 864  
 improvement in, with in-center HD (1993-1995), 851-861  
 rHuEPO resistance and, 567

Uremia  
 effectiveness of renal ultrasound for elevated serum creatinine in, 362-367  
*see also* Chronic renal failure; End-stage renal disease; Hemolytic uremic syndrome

Uremic symptoms in CRF correlated with quality of life, 888-896

Uric acid  
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108  
 in preeclampsia, 347  
 serum, in ARF due to postinfectious GN during pregnancy, 274

Urinary excretion  
 amino acid, in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446  
 in CRF and/or ESRD, *see* Urinary excretion in CRF and/or ESRD  
 K and Cr, in ascitic patients, 394  
 Na, *see* Urinary excretion, Na  
 protein, *see* Urinary excretion, protein  
*see also* Urinary excretion in tubular acidosis and entries ending with suffix: -uria

Urinary excretion, Na  
 in ARF due to postinfectious nephritis in pregnancy, 274  
 ascites and, 394

Urinary excretion, protein  
 in ICGN with HIV and HCV infections, 516  
 in IgAN, 833  
 by membranous nephropathy subjects on lisinopril therapy, 257  
 in SLE, 357  
*see also* Proteinuria

Urinary excretion in CRF and/or ESRD  
 Ca, 643  
 nitrate, ketoconazole plus low-dose prednisone effects on, 503-513  
 P, in secondary HPT with CRF, 499

Urinary excretion in tubular acidosis, 137-141  
 citrate and anion, 140, 141  
 HCO<sub>3</sub>, 137-138, 141, 144  
 NH<sub>4</sub>, 139-141

Urinary pH in tubular acidosis, 139, 141

Urine  
 alkaline, PCO<sub>2</sub> in, in tubular acidosis, 138-139  
 analysis of, of high-school students', 4:A2, 4:A15  
*see also* entries beginning with term: Urinary

Urine volume in ascitic patients, 394

Urolithiasis  
 in PH1, 36-44  
 vasectomy as risk factor for, 207-213

URR, *see* Urea reduction ratio

Uterine vasculitis with SLE and membranous GN, 277-279

Vaccine, HBV, factors influencing Ab response to, in HD patients, 239-245

Valine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

Varices, bleeding esophageal, portal hypertension and, due to ADPKD, 4:A3, 4:A18

Vascular access  
 computerized communication in management of, 4:A2, 4:A18-A19  
*see also* Blood flow, vascular access; Peripheral arteriovenous versus central venous vascular access; Recirculation, vascular access; Vascular access for HD  
 Vascular access for HD, 553-559  
 of ARF, urea sampling measuring access recirculation and, 4:A1, 4:A10-A11  
 of ESRD with HIVAN, 549-552  
 long-term, *see* Long-term vascular access for HD, catheters for  
 Vascular complications, atherosclerotic, in diabetic renal transplant candidates, 601-607

Vascular disease, chronic, GGS with, in FSGS with NS, 339

Vascular resistance, renal, chronic lisinopril and/or fosinopril effects on, 901

Vasculature, *see* Renal vasculature, ET-1 in  
 Vasculitis  
 ANCA-associated, following renal transplantation, outcome of, 96-102  
 uterine, with SLE and membranous GN, 277-279

Vasectomy, as risk factor for urolithiasis, 207-213

Vasoactive agents, GFR regulation by, 972-973

Venous catheters  
 central, paradoxical cerebral air embolism due to, 453-455  
 femoral, recirculation with, 480  
 tunneled permanent, for long-term HD vascular access, 4:A2, 4:A16

Venovenous access, *see* Peripheral arteriovenous versus central venous vascular access

Venovenous disequilibrium in peripheral AV versus CVV access  
 defined, 488  
 in regional blood flow model, 484-486

Ventricular hypertrophy, left, and rHuEPO for predialysis CRF patients, 541-548

Vertical (pseudodominant) pattern of inheritance in PH1, 36-44

Very-low-density lipoprotein(s) (VLDLs), effects of, on mesangial cell proliferation, 919-930

Very-low-density lipoprotein-cholesterol (VLDL-C) in CRF, 57

VIKTOR (universal eating monitor), eating behavior changes in ESRD patients on CAPD and after renal transplantation monitored with, 691-698

Vitamin B<sub>12</sub>, screening for, prior to starting rHuEPO therapy of ESRD patients, 652

Vitamin D for HPT in HD patients, 863

VLDL(s) (very-low-density lipoproteins), effects of, on mesangial cell proliferation, 919-930

VLDL-C (very-low-density lipoprotein-cholesterol) in CRF, 57

Volume loss, compartmental, during HD, 4:A1, 4:A11

WAS (Wiskott-Aldrich syndrome), HSP with IgA abnormalities and IgAN in carrier of, 285-287

Water intake, historical notion of, as nonpharmacological therapy, 777-780

WBCs, *see* White blood cell count and specific white blood cells

Weight  
 kidney, in ADPKD, 267-268

*see also* Body weight  
Weight gain, Na ramping in HD and, 671-673  
White Americans, *see* Race and ethnicity  
White blood cell (WBC) count  
  in ARF due to postinfectious GN during pregnancy, 274  
  in ESRD with HIVAN, 551  
White matter, felodipine for hypertension with multi-infarct disease, impaired cognitive function, and MRI evidence of, 4:A2, 4:A9  
Wiskott-Aldrich syndrome (WAS), HSP with IgA abnormalities and IgAN in carrier of, 285-287  
Withdrawal from chronic HD, 4:A2, 4:A20

Women  
  African American, diabetic nephropathy and risk of ESRD in, 4:A3, 4:A19-A20  
  dialyzed, reproductive and gynecologic issues in, 685-690  
  *see also* Sex and specific conditions

*Xanthomonas maltophilia* (*X. maltophilia*) peritonitis in CAPD patients, 91-95

Young African Americans, SLC associated with insulin resistance and albuminuria in, 45-53

Zinc protoporphyrin (ZPP) in ESRD, 325

